Advaxis (ADXS) 10-K 21 Dec 17 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Oct. 31, 2017	Dec. 15, 2017	Apr. 30, 2017
Document And Entity Information
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	1,100,397
Document Type	10-K
Document Period End Date	Oct. 31, 2017
Amendment Flag	false
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Current Reporting Status	Yes
Current Fiscal Year End Date	--10-31
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 336,054,000
Entity Common Stock, Shares Outstanding		41,303,988
Trading Symbol	ADXS
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Balance Sheets

Balance Sheets - USD ($)	Oct. 31, 2017	Oct. 31, 2016
Current assets:
Cash and cash equivalents	$ 23,899,809	$ 112,750,980
Restricted cash	587,000
Investments	46,398,304	39,336,548
Income tax receivable	4,452,682	2,549,862
Deferred expenses	2,986,385	4,291,385
Prepaid expenses and other current assets	2,918,644	946,423
Total current assets	81,242,824	159,875,198
Property and equipment (net of accumulated depreciation)	7,111,081	4,389,074
Intangible assets (net of accumulated amortization)	4,856,775	4,329,121
Other assets	431,098	450,667
Total assets	93,641,778	169,044,060
Current liabilities:
Accounts payable	5,121,406	1,720,428
Accrued expenses	8,700,036	10,905,003
Deferred revenue	6,995,336	15,020,576
Other current liabilities	47,520	60,382
Total current liabilities	20,864,298	27,706,389
Deferred revenue	17,478,758	21,234,568
Other liabilities	1,038,555	800,909
Total liabilities	39,381,611	49,741,866
Commitments and contingencies - Note 10
Shareholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at October 31, 2017 and 2016. Liquidation preference of $0 at October 31, 2017 and 2016.
Common stock - $0.001 par value; 65,000,000 shares authorized, 41,206,538 shares issued and outstanding at October 31, 2017 and 40,057,067 shares issued and 40,041,047 shares outstanding at October 31, 2016.	41,207	40,057
Additional paid-in capital	355,361,187	327,098,749
Treasury stock, at cost, 0 shares at October 31, 2017 and 16,020 shares October 31, 2016		(129,787)
Accumulated deficit	(301,142,227)	(207,706,825)
Total shareholders' equity	54,260,167	119,302,194
Total liabilities and shareholders' equity	$ 93,641,778	$ 169,044,060

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Oct. 31, 2017	Oct. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Series B Preferred stock, shares issued	0	0
Series B Preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	65,000,000	65,000,000
Common stock, shares issued	41,206,538	40,057,067
Common stock, shares outstanding	41,206,538	40,041,047
Treasury Stock, shares	0	16,020

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
Income Statement [Abstract]
Revenue	$ 12,031,050	$ 3,994,856
Operating expenses:
Research and development expenses	71,900,462	48,774,589	24,455,447
General and administrative expenses	38,658,464	31,712,505	24,243,690
Total operating expenses	110,558,926	80,487,094	48,699,137
Loss from operations	(98,527,876)	(76,492,238)	(48,699,137)
Other income (expense):
Interest income	669,759	331,529	114,219
Net changes in fair value of derivative liabilities	20,156	69,055	(48,950)
Other income (expense), net	(123)	(201)	(6,599)
Net loss before income tax benefit	(97,838,084)	(76,091,855)	(48,640,467)
Income tax benefit	4,402,682	2,535,625	1,609,349
Net loss	$ (93,435,402)	$ (73,556,230)	$ (47,031,118)
Net loss per common share, basic and diluted	$ (2.31)	$ (2.08)	$ (1.68)
Weighted average number of common shares outstanding, basic and diluted	40,527,844	35,400,980	28,026,197

Statements of Shareholders' Equ

Statements of Shareholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Balance at Oct. 31, 2014		$ 19,630	$ 107,601,493		$ (86,991,137)	$ 20,629,986
Balance, shares at Oct. 31, 2014		19,630,139
Stock based compensation		$ 1,169	21,374,861			21,376,030
Stock based compensation, shares		1,167,976
Tax withholdings paid related to net share settlement of equity awards			(1,375,979)			(1,375,979)
Tax withholdings paid on equity awards				$ (1,388,086)		(1,388,086)
Tax withholdings paid on equity awards, shares				(114,445)
Tax shares sold to pay for tax withholdings on equity awards			16,273	$ 1,200,325	(32,004)	1,184,594
Tax shares sold to pay for tax withholdings on equity awards, shares				97,526
Common Stock issued upon exercise of options		$ 65	58,335			$ 58,400
Common Stock issued upon exercise of options, shares		65,167				137,667	[1]
Common Stock issued upon exercise of warrants		$ 691	2,341,758			$ 2,342,449
Common Stock issued upon exercise of warrants, shares		691,268
Conversion of notes payable into common stock		$ 4	39,928			39,932
Conversion of notes payable into common stock, shares		4,104
Issuance of shares to employees under ESPP Plan		$ 7	28,784			28,791
Issuance of shares to employees under ESPP Plan, shares		7,063
Advaxis registered direct offerings		$ 8,806	63,046,722			63,055,528
Advaxis registered direct offerings, shares		8,806,165
Advaxis Public Offering		$ 3,220	56,675,128			56,678,348
Advaxis Public Offering, shares		3,220,000
Net Loss					(47,031,118)	(47,031,118)
Balance at Oct. 31, 2015		$ 33,592	249,807,303	$ (187,761)	(134,054,259)	115,598,875
Balance, shares at Oct. 31, 2015		33,591,882		(16,919)
Stock based compensation		$ 1,043	23,451,904			23,452,947
Stock based compensation, shares		1,042,527
Tax withholdings paid related to net share settlement of equity awards			(61,350)			(61,350)
Tax withholdings paid on equity awards				$ (2,729,230)		(2,729,230)
Tax withholdings paid on equity awards, shares				(332,537)
Tax shares sold to pay for tax withholdings on equity awards			64,110	$ 2,787,204	(96,336)	2,754,978
Tax shares sold to pay for tax withholdings on equity awards, shares				333,436
Common Stock issued upon exercise of warrants		$ 123	614,245			614,368
Common Stock issued upon exercise of warrants, shares		122,661
Conversion of notes payable into common stock		$ 1	29,548			29,549
Conversion of notes payable into common stock, shares		1,481
Issuance of shares to employees under ESPP Plan		$ 7	73,237			73,244
Issuance of shares to employees under ESPP Plan, shares		6,627
Advaxis registered direct offerings		$ 2,244	28,154,163			28,156,407
Advaxis registered direct offerings, shares		2,244,443
Net Loss					(73,556,230)	(73,556,230)
Sale of common shares to Amgen		$ 3,047	24,965,589			24,968,636
Sale of common shares to Amgen, shares		3,047,446
Balance at Oct. 31, 2016		$ 40,057	327,098,749	$ (129,787)	(207,706,825)	119,302,194
Balance, shares at Oct. 31, 2016		40,057,067		(16,020)
Stock based compensation		$ 1,031	27,864,642			27,865,673
Stock based compensation, shares		1,030,507
Tax withholdings paid related to net share settlement of equity awards			(356,949)			(356,949)
Tax withholdings paid on equity awards			(997,029)	$ (881,055)		(1,878,084)
Tax withholdings paid on equity awards, shares				(128,613)
Tax shares sold to pay for tax withholdings on equity awards			843,526	$ 1,010,842		$ 1,854,368
Tax shares sold to pay for tax withholdings on equity awards, shares				144,633
Common Stock issued upon exercise of options, shares
Common Stock issued upon exercise of warrants			1,125			$ 1,125
Common Stock issued upon exercise of warrants, shares		225
Conversion of notes payable into common stock
Issuance of shares to employees under ESPP Plan		$ 27	251,347			251,374
Issuance of shares to employees under ESPP Plan, shares		26,594
Net Loss					(93,435,402)	(93,435,402)
Advaxis at-the-market sales		$ 92	655,776			655,868
Advaxis at-the-market sales, shares		92,145
Balance at Oct. 31, 2017		$ 41,207	$ 355,361,187		$ (301,142,227)	$ 54,260,167
Balance, shares at Oct. 31, 2017		41,206,538
[1]	Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock.

Statement of Cash Flows

Statement of Cash Flows - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
OPERATING ACTIVITIES
Net loss	$ (93,435,402)	$ (73,556,230)	$ (47,031,118)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	27,835,673	23,472,947	21,431,030
Loss (gain) on change in value of warrants and embedded derivative	(20,156)	(69,055)	48,950
Loss (gain) on disposal of property and equipment	3,187		(10,000)
Warrant expense			8,170
Write-off of intangible assets	315,394		28,480
Depreciation expense	790,554	283,538	59,033
Amortization expense of intangible assets	329,866	252,654	206,357
Amortization of premium on held to maturity investments	183,947	252,730	60,608
Debt conversion expense			6,599
Change in operating assets and liabilities:
Prepaid expenses and other current assets	(1,972,221)	(447,167)	(293,096)
Income taxes receivable	(1,902,820)	(940,513)	121,968
Other assets	1,324,569	(3,843,419)	104,529
Accounts payable and accrued expenses	1,159,534	8,354,447	1,094,155
Deferred revenue	(11,781,050)	36,255,144
Other liabilities	244,940	841,135
Net cash used in operating activities	(76,923,985)	(9,143,789)	(24,164,335)
INVESTING ACTIVITIES
Restricted cash established with letter of credit agreement	(587,000)
Purchases of investments	(71,175,703)	(44,524,783)	(45,655,103)
Proceeds from maturities and redemptions of investments	63,930,000	50,530,000
Purchase of property and equipment	(3,449,271)	(3,222,442)	(972,859)
Cost of intangible assets	(1,172,914)	(1,226,742)	(821,925)
Net cash provided by (used in) investing activities	(12,454,888)	1,556,033	(47,449,887)
FINANCING ACTIVITIES
Net proceeds of issuance of common stock	655,868	53,125,043	119,733,876
Proceeds from employee stock purchase plan	251,374	73,244	28,791
Proceeds from exercise of options			58,400
Proceeds from the exercise of warrants	1,125	614,368	2,342,449
Tax withholdings paid related to net share settlement of equity awards	(356,949)	(61,350)	(1,375,979)
Employee tax withholdings paid on equity awards	(1,878,084)	(2,729,230)	(1,388,086)
Tax shares sold to pay for employee tax withholdings on equity awards	1,854,368	2,754,978	1,169,594
Net cash provided by financing activities	527,702	53,777,053	120,569,045
Net increase (decrease) in cash and cash equivalents	(88,851,171)	46,189,297	48,954,823
Cash and cash equivalents at beginning of year	112,750,980	66,561,683	17,606,860
Cash and cash equivalents at end of year	23,899,809	112,750,980	66,561,683
Supplemental Disclosures of Cash Flow Information
Cash paid for interest
Cash paid for taxes	50,000	50,000
Supplemental Schedule of Noncash Investing and Financing Activities
Accounts payable and accrued expenses settled with common stock	75,000	55,000
Conversion of notes payable into common stock		29,549	39,932
Sale of treasury shares pending settlement			15,000
Property and equipment included in accounts payable and accrued expenses	$ 66,477	$ 362,926

Nature of Operations and Basis

Nature of Operations and Basis of Presentation	12 Months Ended
	Oct. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Basis of Presentation	1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION Advaxis, Inc. (“Advaxis” or the “Company”) is a late-stage biotechnology Company focused on the discovery, development and commercialization of proprietary Lm Listeria monocytogenes Lm Lm Lm Lm Advaxis is focused on four franchises in various stages of clinical and pre-clinical development, which they believe will provide the greatest opportunity to have a significant impact on patients and their families: · Human Papilloma Virus (“HPV”)-associated cancers · Neoantigen therapy · Disease focused hotspot / cancer antigen therapies · Prostate cancer All four clinical franchises are anchored in the Company’s Lm TM Lm Lm Liquidity and Financial Condition The Company’s products that are being developed have not generated significant revenue. As a result, the Company has suffered recurring losses. These losses are expected to continue for an extended period of time. Our major sources of cash have been proceeds from various public and private offerings of our common stock, option and warrant exercises, and interest income. From October 2013 through October 2017, we raised approximately $222.5 million in gross proceeds from various public and private offerings of our common stock. As of October 31, 2017, the Company had approximately $70.9 million in cash, restricted cash, cash equivalents and investments on its balance sheet. The Company plans to continue to be disciplined in regards to its utilization of its capital and anticipates its cash burn will decrease from fiscal 2017. This decrease will largely be due to several one-time items in fiscal 2017 related to the preparation of our MAA filing of axalimogene filolisbac and other one-time costs that the Company does not anticipate to recur. We believe our current cash position is sufficient to fund our business plan into fiscal 2019. The actual amount of cash that we will need to operate is subject to many factors. The Company also recognizes it may need to raise additional capital in order to continue to execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Oct. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used when accounting for such items as the fair value and recoverability of the carrying value of property and equipment and intangible assets (patents and licenses), the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may or may not differ from estimates. Reclassification Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss. Collaboration Agreements The Company evaluates whether an arrangement is a collaborative arrangement under the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 808, Collaborative Arrangements, at its inception based on the facts and circumstances specific to the arrangement. The Company also reevaluates whether an arrangement qualifies or continues to qualify as a collaborative arrangement whenever there is a change in either the roles of the participants or the participants’ exposure to significant risks and rewards dependent on the ultimate commercial success of the endeavor. For those collaborative arrangements where it is determined that the Company is the principal participant, costs incurred and revenue generated from third parties are recorded on a gross basis in the financial statements. From time to time, the Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of products and product candidates. These collaborations generally provide for non-refundable, upfront license fees, research and development and commercial performance milestone payments, cost sharing, royalty payments and/or profit sharing. The Company’s collaboration agreements with third parties are performed on a ‘‘best efforts’’ basis with no guarantee of either technological or commercial success. Revenue Recognition The Company is expected to derive the majority of its revenue from patent licensing and research and development services associated with patent licensing. In general, these revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. The intellectual property rights granted may be perpetual in nature, or upon the final milestones being met, or can be granted for a defined, relatively short period of time, with the licensee possessing the right to renew the agreement at the end of each contractual term for an additional minimum upfront payment. The Company recognizes licensing fees when there is persuasive evidence of a licensing arrangement, fees are fixed or determinable, delivery has occurred and collectability is reasonably assured. Revenue associated with nonrefundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected period of performance. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved and the milestone payments are due and collectible. If not deemed substantive, the Company recognizes such milestones as revenue on a straight-line basis over the remaining expected performance period under the arrangement. All such recognized revenues are included in collaborative licensing and development revenue in the Company’s statements of operations. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, and the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services are priced at fair value. If product development is successful, the Company will recognize revenue from royalties based on licensees’ sales of its products or products using its technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received. Deferred revenue represents the portion of payments received for which the earnings process has not been completed. Deferred revenue expected to be recognized within the next 12 months is classified as a current liability. An allowance for doubtful accounts is established based on the Company’s best estimate of the amount of probable credit losses in the Company’s existing license fee receivables, using historical experience. The Company reviews its allowance for doubtful accounts periodically. Past due accounts are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Restricted Cash and Letter of Credit During 2017, the Company established a letter of credit with a financial institution as security for the purchase of custom equipment. The letter of credit is collateralized by cash which is unavailable for withdrawal or for usage for general obligations. No amount is outstanding under the letter of credit as of October 31, 2017. Concentration of Credit Risk The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $23.1 million is subject to credit risk at October 31, 2017. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk. Investments Investment securities consist of certificates of deposit, domestic governmental agency loans, and U.S. treasury notes. The Company classifies these securities as held-to-maturity. Held-to-maturity securities are those securities in which the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method. A decline in the market value of any investment security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges are included in Other Income (Expense), net. The Company did not recognize any impairment charges during the years ended October 31, 2017, 2016 or 2015. Interest income is recognized when earned. Deferred Expenses Deferred expenses consist of advanced payments made on research and development projects. Expense is recognized in the Statement of Operations as the research and development activity is performed. Property and Equipment Property and equipment is stated at cost. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset’s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from three to ten years. When depreciable assets are retired or sold the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations. Intangible Assets Intangible assets are recorded at cost and include patents and patent application costs, licenses and software. Intangible assets are amortized on a straight-line basis over their estimated useful lives ranging from 3 to 20 years. Patent application costs are written-off if the application is rejected, withdrawn or abandoned. Impairment of Long-Lived Assets The company reviews its long-lived assets, including property and equipment and intangible assets, for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated from the use of the asset and its eventual disposition. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, an impairment loss is recognized in the Statement of Operations based on the excess of the carrying amount over the fair value of the asset Net Income (Loss) per Share Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential Common Stock outstanding during the period. In the case of a net loss the impact of the potential Common Stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential Common Stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share. As of October 31, 2017 2016 2015 Warrants 3,092,935 3,110,575 3,241,466 Stock options 3,893,558 3,351,795 1,981,939 Restricted stock units 1,363,119 719,448 1,069,335 Convertible debt (using the if-converted method) - - 1,576 Total 8,349,612 7,181,818 6,294,316 Research and Development Expenses Research and development costs are expensed as incurred and include but are not limited to clinical trial and related manufacturing costs, payroll and personnel expenses, lab expenses, and related overhead costs. Stock Based Compensation The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally measured based on contractual terms. The fair value amount is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the statement of operations, depending on the nature of the services provided by the employees or consultants. The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its Common Stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants. The Company accounts for stock-based compensation using fair value recognition and records forfeitures as they occur. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that vest over their requisite service period, based on the vesting provisions of the individual grants. Treasury Stock The Company accounts for repurchases of common stock and shares withheld in lieu of taxes when restricted stock vests using the cost method with common stock in treasury classified in the balance sheet as a reduction in shareholders’ equity. Fair Value of Financial Instruments The carrying value of financial instruments, including cash and cash equivalents, restricted cash and accounts payable approximated fair value as of the balance sheet date presented, due to their short maturities. The carrying amounts of financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used the Black Scholes valuation model which approximated the binomial lattice options pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months of the balance sheet date. Income Taxes The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized. Recent Accounting Pronouncements In May 2014, as part of its ongoing efforts to assist in the convergence of GAAP and International Financial Reporting Standards, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, which is a new standard related to revenue recognition. Under the new standard, recognition of revenue occurs when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. The standard must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. In July 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers - Deferral of the Effective Date, which defers the implementation of this new standard to be effective for fiscal years beginning after December 15, 2017. Early adoption is permitted effective January 1, 2017. In March 2016, the FASB issued ASU 2016-08, Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations in the new revenue recognition standard pursuant to ASU 2014-09. In April 2016, the FASB issued ASU 2016-10, Identifying Performance Obligations and Licensing, and in May 2016, the FASB issued ASU 2016-12, Narrow-Scope Improvements and Practical Expedients, which amend certain aspects of the new revenue recognition standard pursuant to ASU 2014-09. In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers to clarify the codification or to correct unintended application of guidance. In September and November 2017 , the FASB issued ASU 2017-13 , Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842) and ASU 2017-14, Income Statement—Reporting Comprehensive Income (Topic 220), Revenue Recognition (Topic 605), and Revenue from Contracts with Customers (Topic 606) which amends certain aspects of the new revenue recognition standard The Company is currently evaluating which transition approach we will utilize and the impact of adopting this accounting standard on the Company’s financial statements. In August 2014, the FASB issued ASU 2014-15, Disclosures of Uncertainties About an Entity’s Ability to Continue as a Going Concern. The new standard provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, ending after December 15, 2016. The Company has adopted this standard effective for the year ending October 31, 2017. There was no impact on the Company’s financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The standard amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective beginning in the first quarter of fiscal 2020. Early adoption of ASU 2016-02 is permitted. The new leases standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. In September, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842) which amends certain aspects of the new lease standard. The Company is currently evaluating the impact of adopting ASU 2016-02 on the Company’s financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new standard changes the presentation of restricted cash and cash equivalents on the statement of cash flows. Restricted cash and restricted cash equivalents will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements. In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business.” The amendments in this Update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of businesses. The amendments in this Update provide a screen to determine when a set is not a business. If the screen is not met, it (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace the missing elements. This Update is the final version of Proposed ASU 2015-330 Business Combinations (Topic 805) – Clarifying The Definition of a Business, which has been deleted. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements. In May 2017, the FASB issued ASU 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting” to provide clarity and reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This Update is the final version of Proposed ASU 2016-360—Compensation—Stock Compensation (Topic 718)—Scope of Modification Accounting, which has been deleted. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying consolidated financial statements.

Investments

Investments	12 Months Ended
	Oct. 31, 2017
Schedule of Investments [Abstract]
Investments	3. INVESTMENTS The following table summarizes the Company’s investment securities at amortized cost as of October 31, 2017 and 2016: October 31, 2017 Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value Short-term investments: Certificates of Deposit $ 11,391,147 $ - $ - $ 11,391,147 Domestic Governmental Agency Loans 499,957 - 162 499,795 U.S Treasury Notes 34,507,200 - 25,351 34,481,849 Total short-term investment securities $ 46,398,304 $ - $ 25,513 $ 46,372,791 October 31, 2016 Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value Short-term investments: Certificates of Deposit $ 10,737,563 $ - $ - $ 10,737,563 Domestic Governmental Agency Loans 2,500,000 - 250 2,499,750 U.S Treasury Notes 26,098,985 2,404 7,556 26,093,833 Total short-term investment securities $ 39,336,548 $ 2,404 $ 7,806 $ 39,331,146 All of the Company’s investments mature within the next 12 months.

Property and Equipment

Property and Equipment	12 Months Ended
	Oct. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	4. PROPERTY AND EQUIPMENT Property and equipment consists of the following: October 31, 2017 2016 Leasehold improvements $ 2,167,990 $ 1,835,602 Laboratory equipment 4,381,428 2,038,704 Furniture and fixtures 728,725 549,025 Computer equipment 394,523 240,910 Construction in progress 645,000 151,368 Total property and equipment 8,317,666 4,815,609 Accumulated depreciation and amortization (1,206,585 ) (426,535 ) Net property and equipment $ 7,111,081 $ 4,389,074 Depreciation expense for the years ended October 31, 2017, 2016 and 2015 was $790,554, $283,538 and $59,033, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Oct. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	5. INTANGIBLE ASSETS Intangible assets consist of the following: October 31, 2017 2016 Patents $ 5,727,298 $ 4,980,610 License 776,992 776,992 Software 108,604 19,625 Total intangibles 6,612,894 5,777,227 Accumulated amortization (1,756,119 ) (1,448,106 ) Net intangible assets $ 4,856,775 $ 4,329,121 The expirations of the existing patents range from 2017 to 2038 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. Patent applications having a net book value of $315,394, $0 and $28,480 and were abandoned and were charged to research and development expenses in the Statement of Operations for the years ended October 31, 2017, 2016 and 2015, respectively. Amortization expense for intangible assets is included in general and administrative expenses and aggregated $329,866, $252,654 and $206,357 for the years ended October 31, 2017, 2016 and 2015, respectively. At October 31, 2017, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows: 2018 $ 365,848 2019 363,448 2020 346,593 2021 329,647 2022 329,647 Thereafter 3,121,592 Total $ 4,856,775

Accrued Expenses

Accrued Expenses	12 Months Ended
	Oct. 31, 2017
Payables and Accruals [Abstract]
Accrued Expenses	6. ACCRUED EXPENSES: The following table represents the major components of accrued expenses: October 31, 2017 2016 Salaries and other compensation $ 2,652,583 $ 2,467,650 Vendors 2,811,956 2,098,792 Professional fees 3,235,497 6,338,561 Total accrued expenses $ 8,700,036 $ 10,905,003

Common Stock Purchase Warrants

Common Stock Purchase Warrants and Warrant Liability	12 Months Ended
	Oct. 31, 2017
Common Stock Purchase Warrants And Warrant Liability - Schedule Of Warrants Activity Details Parenthetical
Common Stock Purchase Warrants and Warrant Liability	7. COMMON STOCK PURCHASE WARRANTS AND WARRANT LIABILITY Warrants A summary of warrant activity was as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding and exercisable warrants at October 31, 2014 4,158,092 $ 5.43 3.94 $ 9,518 Issued 2,361 7.20 Exercised * (769,349 ) 5.12 Expired (149,638 ) 14.61 Outstanding and exercisable warrants at October 31, 2015 3,241,466 $ 5.07 2.90 $ 19,588,099 Exercised (122,661 ) 5.01 Expired (8,230 ) 18.75 Outstanding and exercisable warrants at October 31, 2016 3,110,575 $ 5.04 1.91 $ 9,558,159 Exercised (225 ) 5.00 Expired (17,955 ) 11.43 Outstanding and exercisable warrants at October 31, 2017 3,092,395 $ 5.00 0.92 $ - * Includes the cashless exercise of 300,376 warrants that resulted in the issuance of 222,295 shares of common stock. At October 31, 2017, the Company had all of its total 3.09 million outstanding warrants classified as equity (equity warrants). At October 31, 2016, the Company had approximately 3.09 million of its total 3.11 million outstanding warrants classified as equity. At October 31, 2015, the Company had approximately 3.22 million of its total 3.24 million outstanding warrants classified as equity. At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders equity section of the balance sheet. The Company’s equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions. Warrant Liability At October 31, 2017, the Company had no warrants classified as liabilities (liability warrants), as all of the liability warrants expired. At October 31, 2016, the Company had approximately 18,000 of its total 3.11 million outstanding warrants classified as liabilities. At October 31, 2015, the Company had approximately 18,000 of its total 3.24 million outstanding warrants classified as liabilities. The Company utilizes the BSM to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM, to account for the various possibilities that could occur due to changes in the inputs to the BSM as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. As of October 31, 2015, all of the liability warrants that were subject to weighted-average anti-dilution provisions had expired. The remaining liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the Common Stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations. At October 31, 2017 and October 31, 2016, the fair value of the warrant liability was $0 and $20,156, respectively and is reflected in other current liabilities in the Balance Sheet. For the years ended October 31, 2017, 2016 and 2015, the Company reported income of $20,156, income of $69,055 and a loss of $48,950, respectively, due to changes in the fair value of the warrant liability. In fair valuing the warrant liability, at October 31, 2016 and 2015, the Company used the following inputs in its BSM: 10/31/2016 10/31/2015 Exercise price $ 10.63-18.75 $ 10.63-18.75 Stock price $ 8.09 $ 11.09 Expected term 0.55-0.75 years 1.52-1.76 years Volatility % 81.84%-87.09 % 93.87%-95.00 % Risk free rate 0.51%-0.66 % .075 % Warrants with anti-dilution provisions Some of the Company’s warrants contained anti-dilution provisions originally set at an exercise price of $25.00 with a term of five years. As of October 31, 2015, all of these warrants had expired. If the Company had issued any Common Stock, except for exempt issuances as defined in the warrant agreement, for consideration less than the exercise price, then the exercise price and the amount of warrant shares available would have been adjusted to a new price and amount of shares per the “weighted average” formula included in the warrant agreement. For the year ended October 31, 2015, this anti-dilution provision required the Company to issue approximately 2,400 additional warrant shares, and the exercise price to be lowered to $7.20. For those warrants with exercise price reset features (anti-dilution provisions), the Company computed multiple valuations, each quarter, using an adjusted BSM, to account for the various possibilities that could occur due to changes in the inputs to the BSM as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company utilized different exercise prices of $7.20 and $6.00, weighting the possibility of warrants being exercised at $7.20 between 40% and 50% and warrants being exercised at $6.00 between 50% and 60%.

Share Based Compensation

Share Based Compensation	12 Months Ended
	Oct. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share Based Compensation	8. SHARE BASED COMPENSATION The following table summarizes share-based compensation expense included in the Statement of Operations by expense category for the years ended October 31, 2017, 2016 and 2015, respectively: Year Ended October 31, 2017 2016 2015 Research and development $ 5,647,913 $ 7,985,651 $ 6,293,791 General and administrative 22,187,760 15,487,296 15,137,239 Total $ 27,835,673 $ 23,472,947 $ 21,431,030 Amendments The Advaxis, Inc. 2015 Incentive Plan (the “2015 Plan”) was originally ratified and approved by the Company’s stockholders on May 27, 2015. Subject to proportionate adjustment in the event of stock splits and similar events, the aggregate number of shares of Common Stock that may be issued under the 2015 Plan is 3,600,000 shares, plus a number of additional shares (not to exceed 650,000) underlying awards outstanding as of the effective date of the 2015 Plan under the prior planthat thereafter terminate or expire unexercised, or are cancelled, forfeited or lapse for any reason. At the Annual Meeting of Stockholders of the Company held on March 10, 2016, the stockholders ratified and approved an amendment to the 2015 Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan from 3,600,000 shares to 4,600,000 shares. Furthermore, the stockholders approved an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 45,000,000 shares of common stock to 65,000,000 shares of common stock. At the Annual Meeting of Stockholders of the Company held on April 5, 2017, the stockholders ratified and approved an amendment to the 2015 Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan from 4,600,000 shares to 6,100,000 shares. The amendment also included a provision that provides for pre-defined annual increases in the number of shares available for issuance under the Plan equal to the lesser of: (i) 5% of the total number of shares of Common Stock outstanding, (ii) 2,500,000, or (iii) a lesser number determined by the Board of Directors. As of October 31, 2017, there were 710,853 shares available for issuance under the 2015 Plan. Restricted Stock Units (RSUs) A summary of the Company’s RSU activity and related information for the year ended October 31, 2017, 2016 and 2015 is as follows: Number of RSU’s Weighted-Average Grant Date Fair Value Balance at October 31, 2014: 791,879 $ 3.81 Granted 864,192 15.14 Vested (583,403 ) 7.58 Cancelled (3,333 ) 11.76 Balance at October 31, 2015: 1,069,335 $ 10.89 Granted 695,040 9.31 Vested (824,317 ) 8.35 Cancelled (220,610 ) 15.81 Balance at October 31, 2016 719,448 $ 10.77 Granted 1,632,134 7.90 Vested (877,383 ) 9.15 Cancelled (111,080 ) 8.74 Balance at October 31, 2017 1,363,119 $ 8.54 The fair value as of the respective vesting dates of RSUs was approximately $6,045,000, $6,643,000 and $7,771,000 for the years ended October 31, 2017, 2016 and 2015, respectively. As of October 31, 2017, there was approximately $9,434,000 of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.99 years. As of October 31, 2017, the aggregate intrinsic value of non-vested RSUs was approximately $4,635,000. Employee Stock Awards Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 878,948 shares (834,600 shares on a net basis after employee taxes), 719,610 shares (712,106 shares on a net basis after employee taxes), and 506,736 shares (422,781 shares on a net basis after employee taxes) during the years ended October 31, 2017, 2016 and 2015, respectively. Total stock compensation expense associated with these awards for the years ended October 31, 2017, 2016 and 2015 was $8,883,123, $5,458,823 and $5,432,494, respectively. Furthermore, during the year ended October 31, 2015, non-executive employees were entitled to receive a performance-based year-end cash bonus. Several non-executive employees voluntarily requested to be paid all or a portion of their cash bonus in the Company’s common stock instead of cash. During the year ended October 31, 2015, the total fair value of these equity purchases were $102,022, or 9,150 shares of the Company’s Common Stock. Director Stock Awards During the years ended October 31, 2017, 2016 and 2015, common stock issued to the Directors for compensation related to board and committee membership was 30,000 shares, 152,386 shares and 267,186, respectively. During the years ended October 31, 2017, 2016 and 2015, total stock compensation expense to the Directors was $403,200, $1,184,780 and $1,223,118, respectively. Stock Options A summary of changes in the stock option plan for the years ended October 31, 2017, 2016 and 2015 is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding as of October 31, 2014 467,968 $ 15.51 6.34 $ - Granted 1,668,995 13.41 Exercised * (137,667 ) 12.29 Cancelled or expired (17,357 ) 36.24 Outstanding as of October 31, 2015 1,981,939 $ 13.78 8.72 $ 285,330 Granted 1,385,000 12.81 Cancelled or expired (15,144 ) 29.69 Outstanding as of October 31, 2016 3,351,795 $ 13.31 7.82 $ 61,980 Granted 556,952 7.71 Cancelled or expired (15,189 ) 14.07 Outstanding as of October 31, 2017 3,893,558 $ 12.51 5.72 $ - Vested and exercisable at October 31, 2017 2,795,826 $ 13.05 4.80 $ - * Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock. The following table summarizes information about the outstanding and exercisable options at October 31, 2017; Options Outstanding Options Exercisable Weighted Weighted Weighted Weighted Average Average Average Average Exercise Number Remaining Exercise Intrinsic Number Remaining Exercise Intrinsic Price Range Outstanding Contractual Price Value Exercisable Contractual Price Value $3.63 - $9.99 672,672 6.58 $ 7.91 $ 61,980 285,954 4.02 $ 8.19 $ - $10.00 - $14.99 3,006,606 5.63 $ 13.14 $ - 2,295,592 4.95 $ 13.18 $ - $15.01 - $19.99 213,480 4.29 $ 18.07 $ - 213.480 4.29 $ 18.07 $ - $20.00 - $21.25 800 2.60 $ 21.25 $ - 800 2.60 $ 21.25 $ - The fair value of each option granted from the Company’s stock option plans during the years ended October 31, 2017, 2016 and 2015 was estimated on the date of grant using the Black-Scholes option-pricing model. Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of the Company’s Common Stock price, (ii) the periods of time over which employees and Board Directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on the Company’s Common Stock, and (iv) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating expected lives of the options. The Company used their own historical volatility in determining the volatility to be used. The expected term of the stock option grants was calculated using the “simplified” method in accordance with the SEC Staff Accounting Bulletin 107. The “simplified” method was used since the Company believes its historical data does not provide a reasonable basis upon which to estimate expected term and the Company does not have enough option exercise data from its grants issued to support its own estimate as a result of vesting terms and changes in the stock price. The expected dividend yield is zero as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future. The following table provides the weighted average fair value of options granted to directors and employees and the related assumptions used in the Black-Scholes model: Year Ended October 31, 2017 October 31, 2016 October 31, 2015 Weighted average fair value of options granted $ 6.36 $ 10.71 $ 17.38 Expected term 5.50-6.50 years 5.51-6.51 years 5-10 years Expected volatility 107.07%-110.93 % 109.23%-115.25 % 109.26%-154.54 % Expected dividends 0 % 0 % 0 % Risk free interest rate 1.26%-1.58 % 1.65-2.00 % 1.41%-2.27 % Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the years ended October 31, 2017, 2016 and 2015 was approximately $17,195,000, $15,223,000 and $9,521,000, respectively. Included in compensation expense is $1,641,000 recognized as a result of the modification of certain option agreements associated with the resignation of the Company’s Chief Executive Officer in July 2017. Pursuant to the separation agreement all the outstanding options vested immediately and the expiration date was extended until July 5, 2021. During the year ended October 31, 2017, 556,952 options were granted with a total grant date fair value of approximately $3,542,000. During the year ended October 31, 2016, 1,385,000 options were granted with a total grant date fair value of approximately $14,838,000. During the year ended October 31, 2015, 1,668,995 options were granted with a total grant date fair value of approximately $29,014,000. As of October 31, 2017, there was approximately $4,680,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.11 years. Shares Issued to Consultants During the year ended October 31, 2017, 165,907 shares of Common Stock valued at $1,384,350 were issued to consultants for services. The Company recorded a liability on its balance sheet for $45,000 for shares earned pursuant to consulting agreements but not delivered. The common stock share values were based on the dates the shares vested. During the year ended October 31, 2016, 168,885 shares of Common Stock valued at $1,565,888 were issued to consultants for services. The Company recorded a liability on its balance sheet for $75,000 for shares earned pursuant to consulting agreements but not delivered. The common stock share values were based on the dates the shares vested. During the year ended October 31, 2015, 378,538 shares of Common Stock valued at $4,707,440 were issued to consultants for services. The Company recorded a liability on its balance sheet for $55,000 for shares earned pursuant to consulting agreements but not delivered. The common stock share values were based on the dates the shares vested. 2011 Employee Stock Purchase Plan The Advaxis, Inc. 2011 Employee Stock Purchase Plan (“ESPP”) was approved by the Company’s shareholders in September 2011. The ESPP allows employees to purchase Common Stock of the Company at a 15% discount to the market price on designated exercise dates. Employees were eligible to participate in the ESPP beginning December 30, 2011. 40,000 shares of the Company’s Common Stock are reserved for issuance under the ESPP. During the year ended October 31, 2017, 2016 and 2015 shares purchased under the ESPP were 26,594, 6,627 and 7,063 and the Company recorded expense of $251,374, $73,244 and $28,791 respectively. As of October 31, 2017, 0 shares of Company’s Common Stock remain available for issuance under the ESPP.

Collaboration and Licensing Agr

Collaboration and Licensing Agreements	12 Months Ended
	Oct. 31, 2017
Business Combinations [Abstract]
Collaboration and Licensing Agreements	9. COLLABORATION AND LICENSING AGREEMENTS BMS On May 30, 2017, the Company announced a clinical development collaboration with BMS to evaluate ADXS-DUAL, its second investigational immunotherapy targeting HPV-associated cancers, and BMS’ PD-1 immune checkpoint inhibitor, Opdivo ® (nivolumab), as a potential combination treatment option for women with metastatic cervical cancer. Under the terms of the agreement, each party will bear their own internal costs and provide its immunotherapy agent. The Company will sponsor the trial and pay third-party costs. Sellas Life Science Group On February 27, 2017, the Company entered into a license agreement with Sellas Life Science Group (“Sellas”) to develop a novel cancer immunotherapy agent using Advaxis’ proprietary Lm Amgen On August 1, 2016, the Company entered into a global agreement (the “Amgen Agreement”) with Amgen for the development and commercialization of the Company’s ADXS-NEO, a novel, preclinical investigational immunotherapy, using the Company’s proprietary Listeria monocytogenes attenuated bacterial vector which activates a patient’s immune system to respond against unique mutations, or neoepitopes, contained in and identified from an individual patient’s tumor. Under the terms of the Amgen Agreement, Amgen receives an exclusive worldwide license to develop and commercialize ADXS-NEO. Amgen made an upfront payment to Advaxis of $40 million and purchased $25 million of Advaxis common stock. Amgen will fund the clinical development and commercialization of ADXS-NEO and Advaxis will retain manufacturing responsibilities. Advaxis and Amgen will collaborate through a joint steering committee for the development and commercialization of ADXS-NEO. Advaxis will also receive development, regulatory and sales milestone payments of up to $475 million and high single digit to double digit royalty payments based on worldwide sales. The Company identified the following performance obligations under the agreement: 1) the license, 2) the obligation to provide research activities, 3) the obligation to provide clinical supplies, 4) the obligation to perform regulatory functions and 5) the obligation to participate on a Joint Research Committee. The Company considered the provisions of the multiple-element arrangement guidance in determining how to recognize the total consideration of the agreement. The Company determined that none of the deliverables have standalone value; all of these obligations will be delivered throughout the estimated period of performance and therefore are accounted for as a single unit of accounting. Accordingly, the Company recorded the $40 million upfront payment as deferred revenue on the balance sheet and will recognize revenue on a straight-line basis over the estimated period of performance under the Amgen Agreement. Changes in the estimated period of performance will be accounted for prospectively as a change in estimate. During the years ended October 31, 2017 and 2016, the Company recognized revenue from the Amgen Agreement of approximately $11,781,000 and $3,745,000 related to amortization of the upfront fees. In connection with the Amgen Agreement, Amgen purchased directly from Advaxis 3,047,446 shares of the Company’s Common Stock, at approximately $8.20 per share (representing a purchase at market using a 20 day VWAP methodology). The gross proceeds to Advaxis from the sale of the shares was approximately $25 million. The Company considered the provisions of the research and development and collaboration guidance in determining how to recognize the clinical development payments to be received from Amgen. The Company determined the clinical development payments should be accounted for within the scope of collaboration arrangement accounting guidance. As a result, the Company will account for the clinical development payments as a reduction of research and development expenses in the Statement of Operations. During the year ended October 31, 2017, the Company received clinical development payments from Amgen totaling $6,000,000. In addition, the Company recorded an expected clinical development payment of $1,500,000 as prepaid expenses and other current assets on the balance sheet. In November 2017, the Company received the $1,500,000 expected clinical development payment from Amgen. Especificos Stendhal SA de CV On February 3, 2016, the Company entered into a Co-Development and Commercialization Agreement (the “Stendhal Agreement”) with Especificos Stendhal SA de CV (“Stendhal”), for Advaxis’ lead Lm The Company considered the provisions of the research and development and collaboration guidance in determining how to recognize the Support Payments to be received from Stendhal. The Company determined the Stendhal Agreement should be accounted for within the scope of collaboration arrangement accounting guidance. As a result, the Company will account for the support payments as a reduction of research and development expenses in the Statement of Operations. During the year ended October 31, 2017, the Company reached the annual project milestones and received a $3,000,000 Support Payment from Stendhal. Knight Therapeutics On August 26, 2015, the Company entered into a licensing agreement with Knight Therapeutics Inc. (“Knight”), a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products, to commercialize in Canada the Company’s product candidates. Under the terms of the licensing agreement, Knight will be responsible to conduct and fund all regulatory and commercial activities in Canada. The Company is eligible to receive royalty and sales. In connection with the licensing agreement, the Company sold directly to Knight 359,454 shares of the common stock at $13.91 per share Under the terms of the agreement, Knight will be responsible to conduct and fund all regulatory and commercial activities in Canada. We are eligible to receive double digit royalty as well as approximately $33 million in cumulative sales milestones. Merck & Co., Inc. On August 22, 2014, the Company entered into a Clinical Trial Collaboration and Supply Agreement (the “Merck Agreement”) with Merck, pursuant to which the parties are collaborating on a Phase 1/2 dose-determination and safety trial. The Phase 1 portion of the trial evaluated the safety of our Lm Each party is responsible for their own internal costs and expenses to support the trial, while the Company will be responsible for all third party costs of conducting the trial. Merck is responsible for manufacturing and supplying the Merck Compound. The Company is responsible for manufacturing and supplying the Advaxis Compound. The Company is the sponsor of the trial and hold the IND related to the trial. All data and results generated under the trial (“Collaboration Data”) will be jointly owned by the parties, except that ownership of data and information generated from sample analysis to be performed by each party on its respective compound will be owned by the party conducting such testing. All rights to all inventions and discoveries, which claim or cover the combined use of the Advaxis Compound and the Merck Compound shall belong jointly to the parties. Inventions and discoveries relating solely to the Advaxis Compound, or a live attenuated bacterial vaccine, shall be the exclusive property of us. Inventions and discoveries relating solely to the Merck Compound, or a PD-1 antagonist, shall be the exclusive property of Merck. The Merck Agreement shall continue in full force and effect until completion of all of the obligations of the parties or a permitted termination. During the years ended October 31, 2017, 2016 and 2015, the Company incurred approximately $2,925,000, $1,587,000 and $1,723,000, respectively, in expenses pertaining to the Merck agreement, and such expenses were a component of research and development expenses in the statement of operations. MedImmune/AstraZeneca On July 21, 2014, the Company entered into a Clinical Trial Collaboration Agreement (the “MedImmune Agreement”) with MedImmune, the global biologics research and development arm of AstraZeneca, pursuant to which the parties initiated a Phase 1/2 clinical trial in the United States to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with our investigational Lm MedImmune is responsible for providing MEDI4736 at no cost, as well as costs related to the proprietary assays performed by MedImmune or a third party on behalf of MedImmune. The Company is the sponsor of the trial and isresponsible for the submission of all regulatory filings to support the trial, the negotiation and execution of the clinical trial agreements associated with each trial site, and the packaging and labelling of the Advaxis and MedImmune product candidates used in the trial and the costs associated therewith. For a period beginning upon the completion of the trial and the receipt by MedImmune of the last final report for the trial and ending one hundred twenty (120) days thereafter (unless extended), MedImmune will be granted first right to negotiate in good faith in an attempt to enter into an agreement with us with respect to the development, regulatory approval and commercialization of axalimogene filolisbac and MEDI4736 to be used in combination with each other for the treatment or prevention of cancer. Neither party is obligated to enter into such an agreement. In the event the parties do not enter an agreement and we obtain regulatory approval for axalimogene filolisbac in combination with any PD-1 antibody or PD-L1 antibody, we shall pay MedImmune a royalty obligation and one-time payment. All intellectual property rights made, conceived or generated through the clinical trials that relate solely to a MedImmune development product shall be owned solely by MedImmune. All intellectual property rights made, conceived or generated through the clinical trials that relate solely to an Advaxis development product shall be owned solely by us. All intellectual property rights made, conceived or generated through the clinical trials that relate to the combination of one or more MedImmune development product and one or more Advaxis development product shall be jointly owned by both parties; provided, however that in the event the parties do not enter into a clinical development and commercialization agreement, we will not exploit, commercialize or license the joint inventions, except for the performance of its obligations under the MedImmune Agreement. MedImmune has the sole right to prosecute and enforce all patents and other intellectual property rights covering all joint inventions and all associated costs will be shared by the parties. The MedImmune Agreement shall remain in effect until the earlier of (i) permitted termination, (ii) the parties entering into a clinical development and commercialization agreement or expiration of the negotiation period (unless extended), except with respect to rights that survive termination. Either party may terminate the MedImmune Agreement upon thirty (30) days written notice upon material breach of the other party, unless the breach is cured in such period or reasonable actions to cure the breach are initiated and pursued (if the breach is not capable of being cured during the 30-day notice period). In addition, either party may terminate the MedImmune Agreement immediately if the party determines in good faith that the trials may unreasonably affect the safety of trial subjects. During the years ended October 31 2017, 2016 and 2015, the Company incurred approximately $2,787,000, $1,978,000 and $1,888,000, respectively, in expenses pertaining to the MedImmune agreement, and such expenses were a component of research and development expenses in the Statement of Operations. Aratana Therapeutics On March 19, 2014, the Company and Aratana entered into a definitive Exclusive License Agreement (the “Aratana Agreement”). Pursuant to the Agreement, Advaxis granted Aratana an exclusive, worldwide, royalty-bearing, license, with the right to sublicense, certain Advaxis proprietary technology that enables Aratana to develop and commercialize animal health products that will be targeted for treatment of osteosarcoma and other cancer indications in animals. Under the terms of the Aratana Agreement, Aratana paid an upfront payment to the Company, of $1 million. As this license has stand-alone value to Aratana (who has the ability to sublicense) and was delivered to Aratana, upon execution of the Aratana Agreement, the Company recorded the $1 million payment as licensing revenue during the 12 months ended October 31, 2014. Aratana will also pay the Company up to an additional $36.5 million based on the achievement of certain milestones with respect to the advancement of products pursuant to the terms of the Aratana Agreement. In addition, Aratana may pay the Company an additional $15 million in cumulative sales milestones pursuant to the terms of the Aratana Agreement. Advaxis (i) issued and sold 306,122 shares of Advaxis’ Common Stock to Aratana at a price of $4.90 per share, which was equal to the closing price of the Common Stock on the NASDAQ Capital Market on March 19, 2014, and (ii) issued a ten-year warrant to Aratana giving Aratana the right to purchase up to 153,061 additional shares of Advaxis’ Common Stock at an exercise price of $4.90 per share. In connection with the sale of the Common Stock and warrants, Advaxis received aggregate net proceeds of $1,500,000. Biocon Limited On January 20, 2014, we entered into a Distribution and Supply Agreement (“Biocon Agreement”) with Biocon Limited, a company incorporated under the laws of India. Pursuant to the Biocon Agreement, we granted Biocon an exclusive license (with a right to sublicense) to (i) use our data from clinical development activities, regulatory filings, technical, manufacturing and other information and know-how to enable Biocon to submit regulatory filings for axalimogene filolisbac in the following territories: India, Malaysia, Bangladesh, Bhutan, Maldives, Myanmar, Nepal, Pakistan, Sri Lanka, Bahrain, Jordan, Kuwait, Oman, Saudi Arabia, Qatar, United Arab Emirates, Algeria, Armenia, Egypt, Eritrea, Iran, Iraq, Lebanon, Libya, Sudan, Syria, Tunisia and Yemen (collectively, the “Territory”) and (ii) import, promote, market, distribute and sell pharmaceutical products containing axalimogene filolisbac . Global BioPharma Inc. On December 9, 2013, the Company entered into an exclusive licensing agreement for the development and commercialization of axalimogene filolisbac with Global BioPharma, Inc. (“GBP”), a Taiwanese based biotech company funded by a group of investors led by Taiwan Biotech Co., Ltd (TBC). GBP is planning to conduct a randomized Phase 2, open-label, controlled trial in HPV-associated NSCLC in patients following first-line induction chemotherapy. GBP has obtained Taiwanese regulatory approval for this trial and plans to initiate this trial in 2018. This trial will be fully funded exclusively by GBP. GBP will continue to explore the use of our lead product candidate in several other indications including head and neck, and anal cancer. GBP also plans to conduct registration trials with axalimogene filolisbac for the treatment of advanced cervical cancer. GBP will pay Advaxis event-based financial milestones, an annual license fee, and annual net sales royalty payments in the high single to double digits. In addition, as an upfront payment, GBP made an investment in Advaxis of $400,000 by purchasing from the Company 108,724 shares of its Common Stock at a price of $3.68 per share, GBP also received 100,000 warrants at an exercise price of $5.52 which expire in December 2018. GBP will be responsible for all clinical development and commercialization costs in the GBP territory. GBP will also reimburse Advaxis $2.25 million toward AIM2CERV. GBP is committed to establishing manufacturing capabilities for its own. Under the terms of the agreement, we will exclusively license the rights of axalimogene filolisbac to GBP for the Asia, Africa, and former USSR territory, exclusive of India and certain other countries, for all HPV-associated indications. Advaxis will retain exclusive rights to axalimogene filolisbac for the rest of the world. During each of the years ended October 31, 2017 and 2016, the Company recognized revenue of $250,000 for annual license fees.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Oct. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. COMMITMENTS AND CONTINGENCIES Legal Proceedings Knoll On August 21, 2015, Knoll Capital Management L.P. (“KCM”) filed a complaint against the Company in the Delaware Court of Chancery. The complaint alleged the existence of an oral agreement for the purchase by Knoll from the Company of 1,666,666.67 shares of Company stock at a price of $3.00 per share. KCM alleged that the Company breached this alleged agreement and sought specific performance or, alternatively, money damages for breach of contract. KCM served the Company with the complaint on August 31, 2015, and then served an amended complaint on October 16, 2015. The Company moved to dismiss the amended complaint on October 26, 2015 and that motion was denied on January 29, 2016. The Company filed an answer to the amended complaint on February 12, 2016. In lieu of continuing to unnecessarily incur litigation expenses, on April 27, 2017, the Company settled the matter for a non-material amount, predominately reimbursed by the Company’s insurance, and the parties entered into a definitive confidential settlement agreement. The Company expressly denies any admission or wrongdoing and the settlement was entered into solely for the purpose of avoiding the burden, inconvenience, and expense of further litigation. On May 11, 2017, following resolution of the matter by the parties, the Court granted a Stipulation Of Dismissal With Prejudice. Bono On August 20, 2015, a derivative complaint was filed by a purported Company shareholder in the United States District Court for the District of New Jersey styled David Bono v. O’Connor, et al., Case No. 3:15-CV-006326-FLW-DEA (D.N.J. Aug. 20, 2015) (the “Bono Action”). The complaint is based on general allegations related to certain stock options granted to the individual defendants and generally alleges counts for breaches of fiduciary duty and unjust enrichment. The complaint also alleges additional claims for violation of Section 14(a) of the Securities Exchange Act of 1934 and for waste of corporate assets. The complaint seeks damages and costs of an unspecified amount, disgorgement of compensation obtained by the individual defendants, and injunctive relief. Defendants filed a motion to dismiss the Bono Action. On May 23, 2016, the Court issued an opinion and order granting in part and denying in part defendants’ motion to dismiss. On October 5, 2016, the Court denied plaintiff’s motion for reconsideration of its May 23 order. On April 13, 2017, the parties advised the Court that they had reached a tentative agreement in principle to settle the action, subject to negotiating an award of attorneys’ fees and expenses to plaintiff’s counsel and a stipulation of settlement, and, ultimately, Court approval. The parties subsequently executed the stipulation of settlement on October 2, 2017. The Court entered an order preliminarily approving the settlement on November 7, 2017. The final fairness hearing with the Court is presently scheduled for January 29, 2018. Corporate Office & Manufacturing Facility Lease The Company leases its corporate office and manufacturing facility under an operating lease expiring in November, 2025. Future minimum payments under the Company’s operating leases are as follows: Year ended October 31, 2018 $ 1,041,895 2019 1,107,385 2020 1,232,907 2021 1,317,640 2022 1,368,819 Thereafter 4,378,521 Total $ 10,447,167 Rent expense for the years ended October 31, 2017, 2016 and 2015 was $1,188,005, $935,281 and $150,000, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Oct. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	11. INCOME TAXES: The income tax provision (benefit) consists of the following: October 31, 2017 October 31, 2016 October 31, 2015 Federal Current $ - $ - $ - Deferred (34,296,121 ) (18,152,484 ) (14,513,684 ) State and Local Current (4,452,682 ) (2,535,625 ) (1,609,349 ) Deferred (1,123,593 ) (3,698,506 ) (1,840,276 ) Change in valuation allowance 35,419,714 21,850,990 16,353,960 Income tax provision (benefit) $ (4,452,682 ) $ (2,535,625 ) $ (1,609,349 ) The Company has U.S. federal net operating loss carryovers (“NOLs”) of approximately $187,254,000, $137,082,000 and $100,662,000 at October 31, 2017, 2016 and 2015, respectively, available to offset taxable income which expire beginning in 2023. If not used, these NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under the regulations. In fiscal years 2017 and 2016, the Company performed a detailed analysis of any historical and/or current Section 382 ownership changes that may limit the utilization of the net operating loss carryovers. From the entire federal NOL of $187,254,000 as of October 31, 2017, approximately $155,930,000 is available for immediate use based on Internal Revenue Code Section 382 analysis. The NOL and the deferred tax asset table below does not include approximately $24,824,000 of NOL’s that may expire unused. The Company also has New Jersey State Net Operating Loss carryovers of approximately $50,745,000, $66,029,000 and $26,245,000 as of October 31, 2017, 2016 and 2015, respectively, available to offset future taxable income through 2037. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon future generation for taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. The Company evaluated the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability is recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. If applicable, interest costs related to the unrecognized tax benefits are required to be calculated and would be classified as “Other Income (Expense)” in the statement of operations. Penalties would be recognized as a component of “General and Administrative Expenses” in the statement of operations. No interest or penalties on unpaid tax were recorded during the years ended October 31, 2017, 2016 and 2015, respectively. As of October 31, 2017 and 2016, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year. The Company files tax returns in the U.S. federal and state jurisdictions and is subject to examination by tax authorities beginning with the year ended October 31, 2013. The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following: Years Ended October 31, 2017 October 31, 2016 Deferred Tax Assets Net operating loss carryovers $ 66,681,000 $ 51,701,000 Stock-based compensation 21,921,000 15,239,000 Research and development credits 7,293,000 5,672,000 Deferred revenue 9,775,000 - Other deferred tax assets 1,515,000 - Total deferred tax assets $ 107,185,000 $ 72,612,000 Valuation allowance (104,738,000 ) (69,317,000 ) Deferred tax asset, net of valuation allowance $ 2,447,000 $ 3,295,000 Deferred Tax Liabilities Other deferred tax liabilities (2,447,000 ) (3,295,000 ) Total deferred tax liabilities $ (2,447,000 ) $ (3,295,000 ) Net deferred tax asset (liability) $ - $ - The expected tax (expense) benefit based on the statutory rate is reconciled with actual tax expense benefit as follows: Years Ended October 31, 2017 October 31, 2016 October 31, 2015 US Federal statutory rate 34.00 % 34.00 % 34.00 % State income tax, net of federal benefit 1.15 4.86 3.78 Permanent differences (2.30 ) (2.00 ) (1.91 ) Research and development credits 2.36 2.16 2.06 Income tax benefit from sale of New Jersey NOL carryovers 4.55 3.33 3.31 Change in valuation allowance (36.20 ) (28.72 ) (33.62 ) Other 0.99 (10.30 ) (4.31 ) Income tax (provision) benefit 4.55 % 3.33 % 3.31 % Sale of Net Operating Losses (NOLs) The Company may be eligible, from time to time, to receive cash from the sale of its Net Operating Losses under the State of New Jersey NOL Transfer Program. In fiscal 1Q 2018, the Company plans to receive a net cash amount of $4,452,682 from the sale of its state NOLs and research and development tax credits for the period ended October 31, 2016. In November 2016, the Company received a net cash amount of $2,549,862 from the sale of its state NOLs and research and development tax credits for the period ended October 31, 2015. In December 2015, the Company received a net cash amount of $1,609,349 from the sale of its state NOLs and research and development tax credits for the period ended October 31, 2014. Following the receipt of the NOL and research and development tax credit for the period ending October 31, 2016, the Company will have reached the limit under the NJ NOL program and will no longer be able to participate in future sales.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Oct. 31, 2017
Equity [Abstract]
Shareholders' Equity	12. SHAREHOLDERS’ EQUITY: Registered Direct Offerings On August 19, 2016, the Company sold 2,244,443 shares of common stock in a registered direct offering at a per share price of $13.50 for gross proceeds of approximately $30.3 million. The net proceeds to the Company, after deducting the Placement Agents’ fees and other estimated offering expenses payable by the Company, were approximately $28.2 million. On February 18, 2015, the Company priced a registered direct offering of 3,068,095 shares of its Common Stock at $7.50 per share. The transaction closed on February 19, 2015, and the Company received gross proceeds of approximately $23.0 million from the offering. After deducting offering expenses, the net proceeds from the offering were approximately $22.3 million. On December 19, 2014, the Company priced a registered direct offering of 3,940,801 shares of its Common Stock at $4.25 per share. The transaction closed on December 22, 2014, and the Company received gross proceeds of approximately $16.7 million from the offering. After deducting offering expenses, the net proceeds from the offering were approximately $15.8 million. Public Offerings On May 5, 2015, the Company closed on an underwritten public offering of 2,800,000 shares of Common Stock at a public offering price of $19.00 per share. On May 20, 2015, the Company closed the underwriters’ overallotment option to purchase 420,000 shares of its Common Stock at a public offering price of $19.00 per share. The Company received gross proceeds of approximately $61.2 million from the May 2015 public offerings. After deducting offering expenses, the net proceeds from the May 2015 public offerings were approximately $56.7 million.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Oct. 31, 2017
Compensation Related Costs [Abstract]
Employee Benefit Plan	13. EMPLOYEE BENEFIT PLAN The Company sponsors a 401(k) Plan. Employees become eligible for participation upon the start of employment. Participants may elect to have a portion of their salary deferred and contributed to the 401(k) plan up to the limit allowed under the Internal Revenue Code. The Company makes a matching contribution to the plan for each participant who has elected to make tax-deferred contributions for the plan year. The Company made matching contributions which amounted to $449,086, $172,276 and $51,403 for the years ended October 31, 2017, 2016 and 2015, respectively. These amounts were charged to the Statement of Operations. The Employer contributions vest immediately.

Selected Quarterly Financial Da

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Oct. 31, 2017
Quarterly Financial Data [Abstract]
Selected Quarterly Financial Data (Unaudited)	14. SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) The following interim financial information presents the Company’s 2017, 2016 and 2015 results of operations on a quarterly basis (in thousands, except per share amounts): Quarter Ended January 31, 2017 April 30, 2017 July 31, 2017 October 31, 2017 Revenue $ 3,790,842 $ 3,425,380 $ 3,051,620 $ 1,763,208 Net loss (17,081,003 ) (20,467,655 ) (32,625,595 ) (23,261,249 ) Net loss income per common share, basic and diluted (0.43 ) (0.51 ) (0.80 ) (0.57 ) Quarter Ended January 31, 2016 April 30, 2016 July 31, 2016 October 31, 2016 Revenue $ 250,000 $ - $ - $ 3,744,856 Net loss (19,844,935 ) (15,522,450 ) (16,486,008 ) (21,702,837 ) Net loss income per common share, basic and diluted (0.59 ) (0.45 ) (0.48 ) (0.55 ) Quarter Ended January 31, 2015 April 30, 2015 July 31, 2015 October 31, 2015 Revenue $ - $ - $ - $ - Net loss (7,033,870 ) (13,855,259 ) (13,562,026 ) (12,579,963 ) Net loss income per common share, basic and diluted (0.33 ) (0.52 ) (0.44 ) (0.38 )

Subsequent Events

Subsequent Events	12 Months Ended
	Oct. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	15. SUBSEQUENT EVENTS On November 2, 2017, the Company granted to executives 300,000 options with an exercise price of $3.19 and 84,000 performance-based RSU’s (“PRSU’s). The options and PRSU’s vest annually in three equal installments beginning on the first anniversaries of the grant date. On November 2, 2017, the Company granted to Directors 180,000 options with an exercise price of $3.19. The options shall vest in one installment on the first anniversary of the grant date.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Oct. 31, 2017
Accounting Policies [Abstract]
Estimates	Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used when accounting for such items as the fair value and recoverability of the carrying value of property and equipment and intangible assets (patents and licenses), the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may or may not differ from estimates.
Reclassification	Reclassification Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.
Collaboration Agreements	Collaboration Agreements The Company evaluates whether an arrangement is a collaborative arrangement under the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 808, Collaborative Arrangements, at its inception based on the facts and circumstances specific to the arrangement. The Company also reevaluates whether an arrangement qualifies or continues to qualify as a collaborative arrangement whenever there is a change in either the roles of the participants or the participants’ exposure to significant risks and rewards dependent on the ultimate commercial success of the endeavor. For those collaborative arrangements where it is determined that the Company is the principal participant, costs incurred and revenue generated from third parties are recorded on a gross basis in the financial statements. From time to time, the Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of products and product candidates. These collaborations generally provide for non-refundable, upfront license fees, research and development and commercial performance milestone payments, cost sharing, royalty payments and/or profit sharing. The Company’s collaboration agreements with third parties are performed on a ‘‘best efforts’’ basis with no guarantee of either technological or commercial success.
Revenue Recognition	Revenue Recognition The Company is expected to derive the majority of its revenue from patent licensing and research and development services associated with patent licensing. In general, these revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. The intellectual property rights granted may be perpetual in nature, or upon the final milestones being met, or can be granted for a defined, relatively short period of time, with the licensee possessing the right to renew the agreement at the end of each contractual term for an additional minimum upfront payment. The Company recognizes licensing fees when there is persuasive evidence of a licensing arrangement, fees are fixed or determinable, delivery has occurred and collectability is reasonably assured. Revenue associated with nonrefundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected period of performance. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved and the milestone payments are due and collectible. If not deemed substantive, the Company recognizes such milestones as revenue on a straight-line basis over the remaining expected performance period under the arrangement. All such recognized revenues are included in collaborative licensing and development revenue in the Company’s statements of operations. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, and the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services are priced at fair value. If product development is successful, the Company will recognize revenue from royalties based on licensees’ sales of its products or products using its technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received. Deferred revenue represents the portion of payments received for which the earnings process has not been completed. Deferred revenue expected to be recognized within the next 12 months is classified as a current liability. An allowance for doubtful accounts is established based on the Company’s best estimate of the amount of probable credit losses in the Company’s existing license fee receivables, using historical experience. The Company reviews its allowance for doubtful accounts periodically. Past due accounts are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.
Restricted Cash and Letter of Credit	Restricted Cash and Letter of Credit During 2017, the Company established a letter of credit with a financial institution as security for the purchase of custom equipment. The letter of credit is collateralized by cash which is unavailable for withdrawal or for usage for general obligations. No amount is outstanding under the letter of credit as of October 31, 2017.
Concentration of Credit Risk	Concentration of Credit Risk The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $23.1 million is subject to credit risk at October 31, 2017. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.
Investments	Investments Investment securities consist of certificates of deposit, domestic governmental agency loans, and U.S. treasury notes. The Company classifies these securities as held-to-maturity. Held-to-maturity securities are those securities in which the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective interest method. A decline in the market value of any investment security below cost, that is deemed to be other than temporary, results in a reduction in the carrying amount to fair value. The impairment is charged to operations and a new cost basis for the security is established. Other-than-temporary impairment charges are included in Other Income (Expense), net. The Company did not recognize any impairment charges during the years ended October 31, 2017, 2016 or 2015. Interest income is recognized when earned.
Deferred Expenses	Deferred Expenses Deferred expenses consist of advanced payments made on research and development projects. Expense is recognized in the Statement of Operations as the research and development activity is performed.
Property and Equipment	Property and Equipment Property and equipment is stated at cost. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset’s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from three to ten years. When depreciable assets are retired or sold the cost and related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.
Intangible Assets	Intangible Assets Intangible assets are recorded at cost and include patents and patent application costs, licenses and software. Intangible assets are amortized on a straight-line basis over their estimated useful lives ranging from 3 to 20 years. Patent application costs are written-off if the application is rejected, withdrawn or abandoned.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The company reviews its long-lived assets, including property and equipment and intangible assets, for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated from the use of the asset and its eventual disposition. If the total of the undiscounted future cash flows is less than the carrying amount of those assets, an impairment loss is recognized in the Statement of Operations based on the excess of the carrying amount over the fair value of the asset
Net Income (Loss) per Share	Net Income (Loss) per Share Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential Common Stock outstanding during the period. In the case of a net loss the impact of the potential Common Stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential Common Stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share. As of October 31, 2017 2016 2015 Warrants 3,092,935 3,110,575 3,241,466 Stock options 3,893,558 3,351,795 1,981,939 Restricted stock units 1,363,119 719,448 1,069,335 Convertible debt (using the if-converted method) - - 1,576 Total 8,349,612 7,181,818 6,294,316
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred and include but are not limited to clinical trial and related manufacturing costs, payroll and personnel expenses, lab expenses, and related overhead costs.
Stock Based Compensation	Stock Based Compensation The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally measured based on contractual terms. The fair value amount is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the statement of operations, depending on the nature of the services provided by the employees or consultants. The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its Common Stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants. The Company accounts for stock-based compensation using fair value recognition and records forfeitures as they occur. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that vest over their requisite service period, based on the vesting provisions of the individual grants.
Treasury Stock	Treasury Stock The Company accounts for repurchases of common stock and shares withheld in lieu of taxes when restricted stock vests using the cost method with common stock in treasury classified in the balance sheet as a reduction in shareholders’ equity.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of financial instruments, including cash and cash equivalents, restricted cash and accounts payable approximated fair value as of the balance sheet date presented, due to their short maturities. The carrying amounts of financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.
Derivative Financial Instruments	Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used the Black Scholes valuation model which approximated the binomial lattice options pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months of the balance sheet date.
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, as part of its ongoing efforts to assist in the convergence of GAAP and International Financial Reporting Standards, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, which is a new standard related to revenue recognition. Under the new standard, recognition of revenue occurs when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. The standard must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. In July 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers - Deferral of the Effective Date, which defers the implementation of this new standard to be effective for fiscal years beginning after December 15, 2017. Early adoption is permitted effective January 1, 2017. In March 2016, the FASB issued ASU 2016-08, Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations in the new revenue recognition standard pursuant to ASU 2014-09. In April 2016, the FASB issued ASU 2016-10, Identifying Performance Obligations and Licensing, and in May 2016, the FASB issued ASU 2016-12, Narrow-Scope Improvements and Practical Expedients, which amend certain aspects of the new revenue recognition standard pursuant to ASU 2014-09. In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers to clarify the codification or to correct unintended application of guidance. In September and November 2017 , the FASB issued ASU 2017-13 , Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842) and ASU 2017-14, Income Statement—Reporting Comprehensive Income (Topic 220), Revenue Recognition (Topic 605), and Revenue from Contracts with Customers (Topic 606) which amends certain aspects of the new revenue recognition standard The Company is currently evaluating which transition approach we will utilize and the impact of adopting this accounting standard on the Company’s financial statements. In August 2014, the FASB issued ASU 2014-15, Disclosures of Uncertainties About an Entity’s Ability to Continue as a Going Concern. The new standard provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new standard is effective for fiscal years, and interim periods within those fiscal years, ending after December 15, 2016. The Company has adopted this standard effective for the year ending October 31, 2017. There was no impact on the Company’s financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The standard amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective beginning in the first quarter of fiscal 2020. Early adoption of ASU 2016-02 is permitted. The new leases standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. In September, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842) which amends certain aspects of the new lease standard. The Company is currently evaluating the impact of adopting ASU 2016-02 on the Company’s financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new standard changes the presentation of restricted cash and cash equivalents on the statement of cash flows. Restricted cash and restricted cash equivalents will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements. In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business.” The amendments in this Update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of businesses. The amendments in this Update provide a screen to determine when a set is not a business. If the screen is not met, it (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace the missing elements. This Update is the final version of Proposed ASU 2015-330 Business Combinations (Topic 805) – Clarifying The Definition of a Business, which has been deleted. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements. In May 2017, the FASB issued ASU 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting” to provide clarity and reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This Update is the final version of Proposed ASU 2016-360—Compensation—Stock Compensation (Topic 718)—Scope of Modification Accounting, which has been deleted. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying consolidated financial statements.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Oct. 31, 2017
Accounting Policies [Abstract]
Schedule of Common Stock Excluded from Diluted Net Loss Per Share	The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share. As of October 31, 2017 2016 2015 Warrants 3,092,935 3,110,575 3,241,466 Stock options 3,893,558 3,351,795 1,981,939 Restricted stock units 1,363,119 719,448 1,069,335 Convertible debt (using the if-converted method) - - 1,576 Total 8,349,612 7,181,818 6,294,316

Investments (Tables)

Investments (Tables)	12 Months Ended
	Oct. 31, 2017
Schedule of Investments [Abstract]
Schedule of Investment Securities at Amortized	The following table summarizes the Company’s investment securities at amortized cost as of October 31, 2017 and 2016: October 31, 2017 Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value Short-term investments: Certificates of Deposit $ 11,391,147 $ - $ - $ 11,391,147 Domestic Governmental Agency Loans 499,957 - 162 499,795 U.S Treasury Notes 34,507,200 - 25,351 34,481,849 Total short-term investment securities $ 46,398,304 $ - $ 25,513 $ 46,372,791 October 31, 2016 Amortized Cost, as Adjusted Gross Unrealized Holding Gains Gross Unrealized Holding Losses Estimated Fair Value Short-term investments: Certificates of Deposit $ 10,737,563 $ - $ - $ 10,737,563 Domestic Governmental Agency Loans 2,500,000 - 250 2,499,750 U.S Treasury Notes 26,098,985 2,404 7,556 26,093,833 Total short-term investment securities $ 39,336,548 $ 2,404 $ 7,806 $ 39,331,146

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Oct. 31, 2017
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following: October 31, 2017 2016 Leasehold improvements $ 2,167,990 $ 1,835,602 Laboratory equipment 4,381,428 2,038,704 Furniture and fixtures 728,725 549,025 Computer equipment 394,523 240,910 Construction in progress 645,000 151,368 Total property and equipment 8,317,666 4,815,609 Accumulated depreciation and amortization (1,206,585 ) (426,535 ) Net property and equipment $ 7,111,081 $ 4,389,074

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Oct. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	Intangible assets consist of the following: October 31, 2017 2016 Patents $ 5,727,298 $ 4,980,610 License 776,992 776,992 Software 108,604 19,625 Total intangibles 6,612,894 5,777,227 Accumulated amortization (1,756,119 ) (1,448,106 ) Net intangible assets $ 4,856,775 $ 4,329,121
Schedule of Amortization Expense	At October 31, 2017, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows: 2018 $ 365,848 2019 363,448 2020 346,593 2021 329,647 2022 329,647 Thereafter 3,121,592 Total $ 4,856,775

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Oct. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	The following table represents the major components of accrued expenses: October 31, 2017 2016 Salaries and other compensation $ 2,652,583 $ 2,467,650 Vendors 2,811,956 2,098,792 Professional fees 3,235,497 6,338,561 Total accrued expenses $ 8,700,036 $ 10,905,003

Common Stock Purchase Warrant28

Common Stock Purchase Warrants and Warrant Liability (Tables)	12 Months Ended
	Oct. 31, 2017
Common Stock Purchase Warrants And Warrant Liability - Schedule Of Warrants Activity Details Parenthetical
Schedule of Warrants Activity	A summary of warrant activity was as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding and exercisable warrants at October 31, 2014 4,158,092 $ 5.43 3.94 $ 9,518 Issued 2,361 7.20 Exercised * (769,349 ) 5.12 Expired (149,638 ) 14.61 Outstanding and exercisable warrants at October 31, 2015 3,241,466 $ 5.07 2.90 $ 19,588,099 Exercised (122,661 ) 5.01 Expired (8,230 ) 18.75 Outstanding and exercisable warrants at October 31, 2016 3,110,575 $ 5.04 1.91 $ 9,558,159 Exercised (225 ) 5.00 Expired (17,955 ) 11.43 Outstanding and exercisable warrants at October 31, 2017 3,092,395 $ 5.00 0.92 $ - * Includes the cashless exercise of 300,376 warrants that resulted in the issuance of 222,295 shares of common stock.
Schedule of Fair Value of Warrant Liability	In fair valuing the warrant liability, at October 31, 2016 and 2015, the Company used the following inputs in its BSM: 10/31/2016 10/31/2015 Exercise price $ 10.63-18.75 $ 10.63-18.75 Stock price $ 8.09 $ 11.09 Expected term 0.55-0.75 years 1.52-1.76 years Volatility % 81.84%-87.09 % 93.87%-95.00 % Risk free rate 0.51%-0.66 % .075 %

Share Based Compensation (Table

Share Based Compensation (Tables)	12 Months Ended
	Oct. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Share-based Compensation Expense	The following table summarizes share-based compensation expense included in the Statement of Operations by expense category for the years ended October 31, 2017, 2016 and 2015, respectively: Year Ended October 31, 2017 2016 2015 Research and development $ 5,647,913 $ 7,985,651 $ 6,293,791 General and administrative 22,187,760 15,487,296 15,137,239 Total $ 27,835,673 $ 23,472,947 $ 21,431,030
Summary of RSU Activity and Related Information	A summary of the Company’s RSU activity and related information for the year ended October 31, 2017, 2016 and 2015 is as follows: Number of RSU’s Weighted-Average Grant Date Fair Value Balance at October 31, 2014: 791,879 $ 3.81 Granted 864,192 15.14 Vested (583,403 ) 7.58 Cancelled (3,333 ) 11.76 Balance at October 31, 2015: 1,069,335 $ 10.89 Granted 695,040 9.31 Vested (824,317 ) 8.35 Cancelled (220,610 ) 15.81 Balance at October 31, 2016 719,448 $ 10.77 Granted 1,632,134 7.90 Vested (877,383 ) 9.15 Cancelled (111,080 ) 8.74 Balance at October 31, 2017 1,363,119 $ 8.54
Summary of Changes in Stock Option Plan	A summary of changes in the stock option plan for the years ended October 31, 2017, 2016 and 2015 is as follows: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life In Years Aggregate Intrinsic Value Outstanding as of October 31, 2014 467,968 $ 15.51 6.34 $ - Granted 1,668,995 13.41 Exercised * (137,667 ) 12.29 Cancelled or expired (17,357 ) 36.24 Outstanding as of October 31, 2015 1,981,939 $ 13.78 8.72 $ 285,330 Granted 1,385,000 12.81 Cancelled or expired (15,144 ) 29.69 Outstanding as of October 31, 2016 3,351,795 $ 13.31 7.82 $ 61,980 Granted 556,952 7.71 Cancelled or expired (15,189 ) 14.07 Outstanding as of October 31, 2017 3,893,558 $ 12.51 5.72 $ - Vested and exercisable at October 31, 2017 2,795,826 $ 13.05 4.80 $ - * Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock.
Summary of Outstanding and Exercisable Options	The following table summarizes information about the outstanding and exercisable options at October 31, 2017; Options Outstanding Options Exercisable Weighted Weighted Weighted Weighted Average Average Average Average Exercise Number Remaining Exercise Intrinsic Number Remaining Exercise Intrinsic Price Range Outstanding Contractual Price Value Exercisable Contractual Price Value $3.63 - $9.99 672,672 6.58 $ 7.91 $ 61,980 285,954 4.02 $ 8.19 $ - $10.00 - $14.99 3,006,606 5.63 $ 13.14 $ - 2,295,592 4.95 $ 13.18 $ - $15.01 - $19.99 213,480 4.29 $ 18.07 $ - 213.480 4.29 $ 18.07 $ - $20.00 - $21.25 800 2.60 $ 21.25 $ - 800 2.60 $ 21.25 $ -
Summary of Fair Value of Stock Options Granted of BSM	The following table provides the weighted average fair value of options granted to directors and employees and the related assumptions used in the Black-Scholes model: Year Ended October 31, 2017 October 31, 2016 October 31, 2015 Weighted average fair value of options granted $ 6.36 $ 10.71 $ 17.38 Expected term 5.50-6.50 years 5.51-6.51 years 5-10 years Expected volatility 107.07%-110.93 % 109.23%-115.25 % 109.26%-154.54 % Expected dividends 0 % 0 % 0 % Risk free interest rate 1.26%-1.58 % 1.65-2.00 % 1.41%-2.27 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Oct. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Summary of Future Minimum Payments of Operating Leases	Future minimum payments under the Company’s operating leases are as follows: Year ended October 31, 2018 $ 1,041,895 2019 1,107,385 2020 1,232,907 2021 1,317,640 2022 1,368,819 Thereafter 4,378,521 Total $ 10,447,167

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Oct. 31, 2017
Income Tax Disclosure [Abstract]
Components of Income Tax Provision (Benefit)	The income tax provision (benefit) consists of the following: October 31, 2017 October 31, 2016 October 31, 2015 Federal Current $ - $ - $ - Deferred (34,296,121 ) (18,152,484 ) (14,513,684 ) State and Local Current (4,452,682 ) (2,535,625 ) (1,609,349 ) Deferred (1,123,593 ) (3,698,506 ) (1,840,276 ) Change in valuation allowance 35,419,714 21,850,990 16,353,960 Income tax provision (benefit) $ (4,452,682 ) $ (2,535,625 ) $ (1,609,349 )
Schedule of Deferred Tax Assets (Liabilities)	The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following: Years Ended October 31, 2017 October 31, 2016 Deferred Tax Assets Net operating loss carryovers $ 66,681,000 $ 51,701,000 Stock-based compensation 21,921,000 15,239,000 Research and development credits 7,293,000 5,672,000 Deferred revenue 9,775,000 - Other deferred tax assets 1,515,000 - Total deferred tax assets $ 107,185,000 $ 72,612,000 Valuation allowance (104,738,000 ) (69,317,000 ) Deferred tax asset, net of valuation allowance $ 2,447,000 $ 3,295,000 Deferred Tax Liabilities Other deferred tax liabilities (2,447,000 ) (3,295,000 ) Total deferred tax liabilities $ (2,447,000 ) $ (3,295,000 ) Net deferred tax asset (liability) $ - $ -
Reconciliation Expected Tax (Expense) Benefit Based on Statutory Rate with Actual Tax Expense Benefit	The expected tax (expense) benefit based on the statutory rate is reconciled with actual tax expense benefit as follows: Years Ended October 31, 2017 October 31, 2016 October 31, 2015 US Federal statutory rate 34.00 % 34.00 % 34.00 % State income tax, net of federal benefit 1.15 4.86 3.78 Permanent differences (2.30 ) (2.00 ) (1.91 ) Research and development credits 2.36 2.16 2.06 Income tax benefit from sale of New Jersey NOL carryovers 4.55 3.33 3.31 Change in valuation allowance (36.20 ) (28.72 ) (33.62 ) Other 0.99 (10.30 ) (4.31 ) Income tax (provision) benefit 4.55 % 3.33 % 3.31 %

Selected Quarterly Financial 32

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Oct. 31, 2017
Quarterly Financial Data [Abstract]
Summary of Interim Financial Information	The following interim financial information presents the Company’s 2017, 2016 and 2015 results of operations on a quarterly basis (in thousands, except per share amounts): Quarter Ended January 31, 2017 April 30, 2017 July 31, 2017 October 31, 2017 Revenue $ 3,790,842 $ 3,425,380 $ 3,051,620 $ 1,763,208 Net loss (17,081,003 ) (20,467,655 ) (32,625,595 ) (23,261,249 ) Net loss income per common share, basic and diluted (0.43 ) (0.51 ) (0.80 ) (0.57 ) Quarter Ended January 31, 2016 April 30, 2016 July 31, 2016 October 31, 2016 Revenue $ 250,000 $ - $ - $ 3,744,856 Net loss (19,844,935 ) (15,522,450 ) (16,486,008 ) (21,702,837 ) Net loss income per common share, basic and diluted (0.59 ) (0.45 ) (0.48 ) (0.55 ) Quarter Ended January 31, 2015 April 30, 2015 July 31, 2015 October 31, 2015 Revenue $ - $ - $ - $ - Net loss (7,033,870 ) (13,855,259 ) (13,562,026 ) (12,579,963 ) Net loss income per common share, basic and diluted (0.33 ) (0.52 ) (0.44 ) (0.38 )

Nature of Operations and Basi33

Nature of Operations and Basis of Presentation (Details Narrative) - USD ($)	1 Months Ended	49 Months Ended
	May 31, 2015	Oct. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from public offering	$ 56,700,000	$ 222,500,000
Cash, restricted cash, cash equivalents and investments		$ 70,900,000

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Details Narrative)	12 Months Ended
	Oct. 31, 2017USD ($)
Concentration of credit risk	$ 23,100,000
Minimum [Member]
Estimated useful life of intangible assets	3 years
Estimated useful lives of property and equipment	3 years
Research and development term	6 months
Maximum [Member]
Estimated useful life of intangible assets	20 years
Estimated useful lives of property and equipment	10 years
Research and development term	2 years

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Schedule of Common Stock Excluded from Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
Number of common stock excluded from diluted net loss per share	8,349,612	7,181,818	6,294,316
Warrants [Member]
Number of common stock excluded from diluted net loss per share	3,092,935	3,110,575	3,241,466
Stock Options [Member]
Number of common stock excluded from diluted net loss per share	3,893,558	3,351,795	1,981,939
Restricted Stock Units (RSUs) [Member]
Number of common stock excluded from diluted net loss per share	1,363,119	719,448	1,069,335
Convertible Debt [Member]
Number of common stock excluded from diluted net loss per share			1,576

Investments (Details Narrative)

Investments (Details Narrative)	12 Months Ended
	Oct. 31, 2017
Schedule of Investments [Abstract]
Investments maturity description	All of the Company’s investments mature within the next 12 months.

Investments - Schedule of Inves

Investments - Schedule of Investment Securities at Amortized (Details) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016
Amortized Cost, as Adjusted	$ 46,398,304	$ 39,336,548
Gross Unrealized Holding Gains		2,404
Gross Unrealized Holding Losses	25,513	7,806
Estimated Fair Value	46,372,791	39,331,146
Certificates of Deposit [Member]
Amortized Cost, as Adjusted	11,391,147	10,737,563
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Estimated Fair Value	11,391,147	10,737,563
Domestic Governmental Agency Loans [Member]
Amortized Cost, as Adjusted	499,957	2,500,000
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses	162	250
Estimated Fair Value	499,795	2,499,750
U.S Treasury Notes [Member]
Amortized Cost, as Adjusted	34,507,200	26,098,985
Gross Unrealized Holding Gains		2,404
Gross Unrealized Holding Losses	25,351	7,556
Estimated Fair Value	$ 34,481,849	$ 26,093,833

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 790,554	$ 283,538	$ 59,033

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Oct. 31, 2017	Oct. 31, 2016
Property, Plant and Equipment [Abstract]
Leasehold improvements	$ 2,167,990	$ 1,835,602
Laboratory equipment	4,381,428	2,038,704
Furniture and fixtures	728,725	549,025
Computer equipment	394,523	240,910
Construction in progress	645,000	151,368
Total property and equipment	8,317,666	4,815,609
Accumulated depreciation and amortization	(1,206,585)	(426,535)
Net property and equipment	$ 7,111,081	$ 4,389,074

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Finite lived patents expirations year	The expirations of the existing patents range from 2017 to 2038
Amortization expense of licensed technology and capitalized patent costs	$ 329,866	$ 252,654	$ 206,357
Book value patent applications, net	$ 315,394	$ 0	$ 28,480

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets (Details) - USD ($)	Oct. 31, 2017	Oct. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 5,727,298	$ 4,980,610
License	776,992	776,992
Software	108,604	19,625
Total intangibles	6,612,894	5,777,227
Accumulated amortization	(1,756,119)	(1,448,106)
Net intangible assets	$ 4,856,775	$ 4,329,121

Intangible Assets - Schedule of

Intangible Assets - Schedule of Amortization Expense (Details)	Oct. 31, 2017USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,018	$ 365,848
2,019	363,448
2,020	346,593
2,021	329,647
2,022	329,647
Thereafter	3,121,592
Total	$ 4,856,775

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Oct. 31, 2017	Oct. 31, 2016
Payables and Accruals [Abstract]
Salaries and other compensation	$ 2,652,583	$ 2,467,650
Vendors	2,811,956	2,098,792
Professional fees	3,235,497	6,338,561
Total accrued expenses	$ 8,700,036	$ 10,905,003

Common Stock Purchase Warrant44

Common Stock Purchase Warrants and Warrant Liability (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015	Oct. 31, 2014
Warrants outstanding	3,092,395	3,110,575	3,241,466	4,158,092
Fair value of warrant liability	$ 0	$ 20,156	$ 89,211
Gain (loss) on change in fair value of warrant liability	$ 20,156	$ 69,055	$ 48,950
Warrants term	5 years
Anti-dilution provisions warrants exercise price	$ 25
Anti-dilution provisions additional warrants issuable			2,400
Equity Warrants [Member]
Warrants outstanding	309,000	309,000	3,220,000
Liability Warrant [Member]
Warrants outstanding	0	3,110,000	3,240,000
Number of warrants		18,000	18,000
Warrants With Anti Dilution Provisions [Member]
Anti-dilution provisions warrants exercise price			$ 7.20
Warrants With Anti Dilution Provisions [Member] | Exercise Price Range 7.20 [Member]
Anti-dilution provisions warrants exercise price	$ 7.20
Probability of exercise of additional warrants at exercise price one	40.00%
Probability of exercise of additional warrants at exercise price two	50.00%
Warrants With Anti Dilution Provisions [Member] | Exercise Price Range 6.00 [Member]
Anti-dilution provisions warrants exercise price	$ 6
Probability of exercise of additional warrants at exercise price one	50.00%
Probability of exercise of additional warrants at exercise price two	60.00%

Common Stock Purchase Warrant45

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) - USD ($)	12 Months Ended
	Oct. 31, 2017		Oct. 31, 2016	Oct. 31, 2015
Common Stock Purchase Warrants And Warrant Liability - Schedule Of Warrants Activity Details Parenthetical
Number of Warrants, Outstanding, Beginning balance	3,110,575		3,241,466	4,158,092
Number of Warrants, Issued				2,361
Number of Warrants, Exercised	(225)	[1]	(122,661)	(769,349)	[1]
Number of Warrants, Expired	(17,955)		(8,230)	(149,638)
Number of Warrants, Outstanding, Ending balance	3,092,395		3,110,575	3,241,466
Weighted-Average Exercise Price, Outstanding, Beginning	$ 5.04		$ 5.07	$ 5.43
Weighted-Average Exercise Price, Issued				7.20
Weighted-Average Exercise Price, Exercised	5	[1]	5.01	5.12	[1]
Weighted-Average Exercise Price, Expired	11.43		18.75	14.61
Weighted-Average Exercise Price, Outstanding, Ending	$ 5		$ 5.04	$ 5.07
Weighted Average Remaining Contractual Life In Years, Beginning	1 year 10 months 28 days		2 years 10 months 25 days	3 years 11 months 8 days
Weighted Average Remaining Contractual Life In Years, Ending	11 months 1 day		1 year 10 months 28 days	2 years 10 months 25 days
Aggregate Intrinsic Value, Beginning	$ 9,558,159		$ 19,588,099	$ 9,518
Aggregate Intrinsic Value, Ending			$ 9,558,159	$ 19,588,099
[1]	Includes the cashless exercise of 300,376 warrants that resulted in the issuance of 222,295 shares of common stock.

Common Stock Purchase Warrant46

Common Stock Purchase Warrants and Warrant Liability - Schedule of Warrants Activity (Details) (Parenthetical)	12 Months Ended
	Oct. 31, 2015shares
Common Stock Purchase Warrants And Warrant Liability - Schedule Of Warrants Activity Details Parenthetical
Cashless exercise of warrants	300,376
Issuance of common stock	222,295

Common Stock Purchase Warrant47

Common Stock Purchase Warrants and Warrant Liability - Schedule of Fair Value of Warrant Liability (Details) - $ / shares	12 Months Ended
	Oct. 31, 2016	Oct. 31, 2015
Stock price	$ 8.09	$ 11.09
Risk free rate		0.075%
Minimum [Member]
Exercise price	$ 10.63	$ 10.63
Expected term	6 months 18 days	1 year 6 months 7 days
Volatility %	81.84%	93.87%
Risk free rate	0.51%
Maximum [Member]
Exercise price	$ 18.75	$ 18.75
Expected term	9 months	1 year 9 months 3 days
Volatility %	87.09%	95.00%
Risk free rate	0.66%

Share Based Compensation (Detai

Share Based Compensation (Details Narrative) - USD ($)	Apr. 05, 2017	Aug. 19, 2016	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015	Oct. 31, 2014	Mar. 10, 2016	Sep. 30, 2011
Issuance of common stock		2,244,443
Common stock authorized for issuance			65,000,000	65,000,000
Common stock, shares outstanding			41,206,538	40,041,047
Stock compensation expense			$ 1,641,000
Stock option vested expiration date			Jul. 5, 2021
Unrecognized compensation cost related to non-vested stock option awards			$ 4,680,000
Unrecognized compensation cost related to non-vested remaining weighted average vesting period			1 year 11 months 26 days
Options outstanding, intrinsic value				$ 61,980	$ 285,330
Compensation cost related to outstanding stock options			$ 17,195,000	$ 15,223,000	$ 9,521,000
Number of options, granted			556,952	1,385,000	1,668,995
Fair value of option granted			$ 3,542,000	$ 14,838,000	$ 29,014,000
Proceeds from common stock exercise					58,400
Restricted Stock Units (RSUs) [Member]
Fair value of equity purchases value			6,045,000	$ 6,643,000	$ 7,771,000
Unrecognized compensation cost related to non-vested stock option awards			9,434,000
Options outstanding, intrinsic value			$ 4,635,000
Number of options, granted			1,632,134	695,040	864,192	1,268,580
Employee Stock Awards [Member]
Share-based compensation, common stock, shares			878,948	719,610	506,736
Share-based compensation, shares on net basis after employee payroll taxes			834,600	712,106	422,781
Stock compensation expense			$ 8,883,123	$ 458,823	$ 5,432,494
Director Stock Awards [Member]
Share-based compensation, common stock, shares			30,000	152,386	267,186
Stock compensation expense			$ 403,200	$ 1,184,780	$ 1,223,118
Consultants [Member]
Stock issued during period for services			165,907	168,885	378,538
Stock issued during period value for services			$ 1,384,350	$ 1,565,888	$ 4,707,440
Consultants [Member]
Recorded a liability			$ 45,000	$ 75,000	$ 55,000
Additional Shares [Member]
Issuance of common stock			650,000
Stock Split [Member]
Issuance of common stock			3,600,000
2015 Plan [Member]
Shares of common stock outstanding, percentage	5.00%
Common stock, shares outstanding	2,500,000
Common stock reserved for issuance under plan			710,853
2015 Plan [Member] | Minimum [Member]
Common stock authorized for issuance	4,600,000		45,000,000				3,600,000
2015 Plan [Member] | Maximum [Member]
Common stock authorized for issuance	6,100,000		65,000,000				4,600,000
2011 Employee Stock Purchase Plan [Member]
Common stock reserved for issuance under plan			26,594	6,627	7,063			40,000
Fair value of equity purchases value					$ 102,022
Number of shares for equity purchases					9,150
Discount price percentage								15.00%
Expenses recorded under the plan			$ 251,374	$ 73,244	$ 28,791
Remaining number of shares available for issuance under the plan			0

Share Based Compensation - Summ

Share Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
Share-based compensation expense	$ 27,835,673	$ 23,472,947	$ 21,431,030
Research and Development [Member]
Share-based compensation expense	5,647,913	7,985,651	6,293,791
General and Administrative [Member]
Share-based compensation expense	$ 22,187,760	$ 15,487,296	$ 15,137,239

Share Based Compensation - Su50

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - $ / shares		12 Months Ended
		Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015		Oct. 31, 2014
Beginning Balance		3,351,795	1,981,939	467,968
Number of RSUs Granted		556,952	1,385,000	1,668,995
Number of RSUs Vested				(137,667)	[1]
Number of RSUs Cancelled		(15,189)	(15,144)	(17,357)
Ending Balance		3,893,558	3,351,795	1,981,939		467,968
Weighted-Average Exercise Price, Outstanding, Beginning		$ 13.31	$ 13.78	$ 15.51
Weighted-Average Exercise Price, Granted		7.71	12.81	13.41
Weighted-Average Exercise Price, Vested	[1]			12.29
Weighted-Average Exercise Price, Cancelled		14.07	29.69	36.24
Weighted-Average Exercise Price, Outstanding, Ending		$ 12.51	$ 13.31	$ 13.78		$ 15.51
Restricted Stock Units (RSUs) [Member]
Beginning Balance		719,448	1,069,335	791,879
Number of RSUs Granted		1,632,134	695,040	864,192		1,268,580
Number of RSUs Vested		(877,383)	(824,317)	(583,403)
Number of RSUs Cancelled		(111,080)	(220,610)	(3,333)
Ending Balance		1,363,119	719,448	1,069,335		791,879
Weighted-Average Exercise Price, Outstanding, Beginning		$ 10.77	$ 10.89	$ 3.81
Weighted-Average Exercise Price, Granted		7.90	9.31	15.14
Weighted-Average Exercise Price, Vested		9.15	8.35	7.58
Weighted-Average Exercise Price, Cancelled		8.74	15.81	11.76
Weighted-Average Exercise Price, Outstanding, Ending		$ 8.54	$ 10.77	$ 10.89		$ 3.81
[1]	Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock.

Share Based Compensation - Su51

Share Based Compensation - Summary of Changes in Stock Option Plan (Details) - USD ($)		12 Months Ended
		Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Beginning Balance		3,351,795	1,981,939	467,968
Number of Options, Granted		556,952	1,385,000	1,668,995
Number of Options, Exercised				(137,667)	[1]
Number of Options, Expired		(15,189)	(15,144)	(17,357)
Ending Balance		3,893,558	3,351,795	1,981,939
Number of Options, Vested and Exercisable		2,795,826
Weighted-Average Exercise Price, Outstanding, Beginning		$ 13.31	$ 13.78	$ 15.51
Weighted-Average Exercise Price, Granted		7.71	12.81	13.41
Weighted-Average Exercise Price, Exercised	[1]			12.29
Weighted-Average Exercise Price, Expired		14.07	29.69	36.24
Weighted-Average Exercise Price, Outstanding, Ending		12.51	$ 13.31	$ 13.78
Weighted-Average Exercise Price, Vested and Exercisable		$ 13.05
Weighted Average Remaining Contractual Life In Years, Beginning		7 years 9 months 25 days	8 years 8 months 19 days	6 years 4 months 2 days
Weighted Average Remaining Contractual Life In Years, Ending		5 years 8 months 19 days	7 years 9 months 25 days	8 years 8 months 19 days
Weighted Average Remaining Contractual Life In Years, Vested and Exercisable		4 years 9 months 18 days
Aggregate Intrinsic Value, Beginning		$ 61,980	$ 285,330
Aggregate Intrinsic Value, Ending			$ 61,980	$ 285,330
[1]	Includes the cashless exercise of 117,667 options that resulted in the issuance of 45,167 shares of common stock.

Share Based Compensation - Su52

Share Based Compensation - Summary of Changes in Stock Option Plan (Details) (Parenthetical)	12 Months Ended
	Oct. 31, 2015shares
Cashless exercise of warrants	300,376
Issuance of common stock	222,295
Stock Options [Member]
Cashless exercise of warrants	117,667
Issuance of common stock	45,167

Share Based Compensation - Su53

Share Based Compensation - Summary of Outstanding and Exercisable Options (Details) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015	Oct. 31, 2014
Options Outstanding, Number Outstanding	3,893,558	3,351,795	1,981,939	467,968
Options Outstanding, Weighted Average Exercise Price	$ 12.51	$ 13.31	$ 13.78	$ 15.51
Options Outstanding, Intrinsic Value		$ 61,980	$ 285,330
Options Exercisable, Number Outstanding	2,795,826
Options Exercisable, Weighted Average Exercise Price	$ 13.05
Exercise Price Range 3.63 - $9.99 [Member]
Range , lower limit	3.63
Range , upper limit	$ 9.99
Options Outstanding, Number Outstanding	672,672
Options Weighted Average Remaining Contractual Term	6 years 6 months 29 days
Options Outstanding, Weighted Average Exercise Price	$ 7.91
Options Outstanding, Intrinsic Value	$ 61,980
Options Exercisable, Number Outstanding	285,954
Options Weighted Average Remaining Contractual Term Exercisable	4 years 7 days
Options Exercisable, Weighted Average Exercise Price	$ 8.19
Options Exercisable, Intrinsic Value
Exercise Price Range $10.00 - $14.99 [Member]
Range , lower limit	$ 10
Range , upper limit	$ 14.99
Options Outstanding, Number Outstanding	3,006,606
Options Weighted Average Remaining Contractual Term	5 years 7 months 17 days
Options Outstanding, Weighted Average Exercise Price	$ 13.14
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding	2,295,592
Options Weighted Average Remaining Contractual Term Exercisable	4 years 11 months 12 days
Options Exercisable, Weighted Average Exercise Price	$ 13.18
Options Exercisable, Intrinsic Value
Exercise Price Range $15.01 - $19.99 [Member]
Range , lower limit	$ 15.01
Range , upper limit	$ 19.99
Options Outstanding, Number Outstanding	213,480
Options Weighted Average Remaining Contractual Term	4 years 3 months 15 days
Options Outstanding, Weighted Average Exercise Price	$ 18.07
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding	213,480
Options Weighted Average Remaining Contractual Term Exercisable	4 years 3 months 15 days
Options Exercisable, Weighted Average Exercise Price	$ 18.07
Options Exercisable, Intrinsic Value
Exercise Price Range $20.00 - $25.00 [Member]
Range , lower limit	$ 20
Range , upper limit	$ 21.25
Options Outstanding, Number Outstanding	800
Options Weighted Average Remaining Contractual Term	2 years 7 months 6 days
Options Outstanding, Weighted Average Exercise Price	$ 21.25
Options Outstanding, Intrinsic Value
Options Exercisable, Number Outstanding	800
Options Weighted Average Remaining Contractual Term Exercisable	2 years 7 months 6 days
Options Exercisable, Weighted Average Exercise Price	$ 21.25
Options Exercisable, Intrinsic Value

Share Based Compensation - Su54

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details) - $ / shares	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
Weighted average fair value of options granted	$ 6.36	$ 10.71	$ 17.38
Expected Volatility, Minimum	107.07%	109.23%	109.26%
Expected Volatility, Maximum	110.93%	115.25%	154.54%
Expected Dividends	0.00%	0.00%	0.00%
Risk Free Interest Rate, Minimum	1.26%	1.65%	1.41%
Risk Free Interest Rate, Maximum	1.58%	2.00%	2.27%
Minimum [Member]
Expected Term	5 years 6 months	5 years 6 months 3 days	5 years
Maximum [Member]
Expected Term	6 years 6 months	6 years 6 months 3 days	10 years

Collaboration and Licensing A55

Collaboration and Licensing Agreements (Details Narrative) - USD ($)	Feb. 27, 2017	Aug. 02, 2016	Feb. 03, 2016	Aug. 26, 2015	Mar. 19, 2014	Dec. 09, 2013	Nov. 30, 2017	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015	Aug. 19, 2016	May 20, 2015	May 05, 2015	Feb. 18, 2015	Dec. 19, 2014
Number of common stock shares								41,206,538	40,057,067
Common stock purchase price per share											$ 13.50	$ 19	$ 19	$ 7.50	$ 4.25
Proceeds form issuance of stock								$ 655,868	$ 53,125,043	$ 119,733,876
Amgen Agreement [Member]
Development, regulatory and sales milestone payments		$ 475,000,000
Upfront payment		40,000,000
Value of stock purchased		25,000,000
Upfront payment recorded as deferred revenue		$ 40,000,000
Business combination amount transferred								11,781,000	3,745,000
Number of common stock shares		3,047,446
Common stock purchase price per share		$ 8.20
Proceeds form issuance of stock		$ 25,000,000
Proceeds from clinical developoment							$ 1,500,000	6,000,000
Stendhal Agreement [Member]
Support payments expenses			$ 10,000,000
Aratana Agreement [Member]
Development, regulatory and sales milestone payments					$ 36,500,000
Upfront payment					$ 1,000,000
Number of common stock shares					306,122
Common stock purchase price per share					$ 4.90
Licensing revenue					$ 1,000,000
Aratana Agreement [Member] | Warrants [Member]
Number of common stock shares					153,061
Common stock purchase price per share					$ 4.90
Proceeds form issuance of stock					$ 1,500,000
Warrant term					10 years
Sellas Life Science Group [Member]
Development, regulatory and sales milestone payments	$ 358,000,000
Knight [Member]
Number of common stock shares				359,454
Common stock purchase price per share				$ 13.91
Knight TherapeuticsInc [Member]
Proceeds from royalty received				$ 33,000,000
Merck Agreement [Member]
Agreement expenses								2,925,000	1,587,000	1,723,000
MedImmune Agreement [Member]
Agreement expenses								2,787,000	1,978,000	$ 1,888,000
Aratana Agreement [Member]
Value of stock purchased						$ 400,000
Number of common stock shares						108,724
Common stock purchase price per share						$ 3.68
Licensing revenue								250,000	$ 250,000
Reimbursement value								$ 22,500,000
Aratana Agreement [Member] | Warrants [Member]
Number of common stock shares						100,000
Common stock purchase price per share						$ 5.52

Commitments and Contingencies56

Commitments and Contingencies (Details Narrative) - USD ($)	Aug. 21, 2015	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
Rent expense		$ 1,188,005	$ 935,281	$ 150,000
Corporate Office & Manufacturing Facility Lease [Member]
Agreement expiration date		Nov. 30, 2025
KCM [Member]
Number of shares complaint alleges of common stock	1,666,666.67
Common stock price per share	$ 3

Commitments and Contingencies -

Commitments and Contingencies - Summary of Future Minimum Payments of Operating Leases (Details)	Oct. 31, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 1,041,895
2,019	1,107,385
2,020	1,232,907
2,021	1,317,640
2,022	1,368,819
Thereafter	4,378,521
Total	$ 10,447,167

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015	Oct. 31, 2014
U.s. Federal net operating loss carryovers (NOLs)	$ 187,254,000	$ 137,082,000	$ 100,662,000
Operating loss expiration year	2,023
Minimum percentage of ownership change as determined under regulations	50.00%	50.00%
New jersey state net operating loss carryovers	$ 50,745,000	$ 66,029,000	26,245,000
Net operating loss and DTA dose not include nol's	24,824,000
Interest or penalties on unpaid tax	0	0	0
Liability for unrecognized tax benefits	0	0	0
January 2018 [Member]
Net cash amount received from sale of net operating losses and research and development tax credits		$ 4,452,682
November 2016 [Member]
Net cash amount received from sale of net operating losses and research and development tax credits			$ 2,549,862
December 2015 [Member]
Net cash amount received from sale of net operating losses and research and development tax credits				$ 1,609,349
Internal Revenue Code [Member]
U.s. Federal net operating loss carryovers (NOLs)	$ 155,930,000

Income Taxes - Components of In

Income Taxes - Components of Income Tax Provision (Benefit) (Details) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
Income Tax Disclosure [Abstract]
Current Federal
Deferred Federal	(34,296,121)	(18,152,484)	(14,513,684)
Current State and Local	(4,452,682)	(2,535,625)	(1,609,349)
Deferred State and Local	(1,123,593)	(3,698,506)	(1,840,276)
Change in valuation allowance	35,419,714	21,850,990	16,353,960
Income tax provision (benefit)	$ (4,402,682)	$ (2,535,625)	$ (1,609,349)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Details) - USD ($)	Oct. 31, 2017	Oct. 31, 2016
Income Tax Disclosure [Abstract]
Net operating loss carryovers	$ 66,681,000	$ 51,701,000
Stock-based compensation	21,921,000	15,239,000
Research and development credits	7,293,000	5,672,000
Deferred revenue	9,775,000
Other deferred tax assets	1,515,000
Total deferred tax assets	107,185,000	72,612,000
Valuation allowance	(104,738,000)	(69,317,000)
Deferred tax asset, net of valuation allowance	2,447,000	3,295,000
Other deferred tax liabilities	(2,447,000)	(3,295,000)
Total deferred tax liabilities	(2,447,000)	(3,295,000)
Net deferred tax asset (liability)

Income Taxes - Reconciliation E

Income Taxes - Reconciliation Expected Tax (Expense) Benefit Based on Statutory Rate with Actual Tax Expense Benefit (Details)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
Income Tax Disclosure [Abstract]
US Federal statutory rate	34.00%	34.00%	34.00%
State income tax, net of federal benefit	1.12%	4.86%	3.78%
Permanent differences	(2.30%)	2.00%	(1.91%)
Research and development	2.36%	2.16%	2.06%
Income tax benefit from sale of New Jersey NOL carryovers	4.55%	3.33%	3.31%
Change in valuation allowance	(36.20%)	(28.72%)	(33.62%)
Other	0.99%	(10.30%)	(4.31%)
Income tax (provision) benefit	4.55%	3.33%	3.31%

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)	Aug. 19, 2016	May 20, 2015	May 05, 2015	Feb. 18, 2015	Dec. 19, 2014	May 31, 2015	Oct. 31, 2017
Equity [Abstract]
Number of common stock shares sold	2,244,443
Common stock price per share	$ 13.50	$ 19	$ 19	$ 7.50	$ 4.25
Gross proceeds from public offering	$ 30,300,000					$ 61,200,000
Net proceeds after deducting the placement agents' fees and other estimated offering expenses	$ 28,200,000
Number of shares issued during period for registered direct offering				3,068,095	3,940,801
Proceeds received from offering				$ 23,000,000	$ 16,700,000
Proceeds from registered direct offering, net of offering expenses				$ 22,300,000	$ 15,800,000
Number of common stock shares issued for public offering			2,800,000
Number of overallotment option to purchase of common stock shares		420,000
Proceeds from public offering						$ 56,700,000	$ 222,500,000

Employee Benefit Plan (Details

Employee Benefit Plan (Details Narrative) - USD ($)	12 Months Ended
	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
401(k) Plan [Member]
Employee contributions, amount	$ 449,086	$ 172,276	$ 51,403

Selected Quarterly Financial 64

Selected Quarterly Financial Data (Unaudited) - Summary of Interim Financial Information (Details) - USD ($)	3 Months Ended			6 Months Ended			9 Months Ended			12 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2015	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
Net loss										$ (93,435,402)	$ (73,556,230)	$ (47,031,118)
Net loss income per common share, basic and diluted										$ (2.31)	$ (2.08)	$ (1.68)
Interim Financial Report [Member]
Revenue	$ 3,790,842	$ 250,000		$ 3,425,380			$ 3,051,620			$ 1,763,208	$ 3,744,856
Net loss	$ (17,081,003)	$ (19,844,935)	$ (7,033,870)	$ (20,467,655)	$ (15,522,450)	$ (13,855,259)	$ (32,625,595)	$ (16,486,008)	$ (13,562,026)	$ (23,261,249)	$ (21,702,837)	$ (12,579,963)
Net loss income per common share, basic and diluted	$ (0.43)	$ (0.59)	$ (0.33)	$ (0.51)	$ (0.45)	$ (0.52)	$ (0.80)	$ (0.48)	$ (0.44)	$ (0.57)	$ (0.55)	$ (0.38)

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - $ / shares	Nov. 02, 2017	Oct. 31, 2017	Oct. 31, 2016	Oct. 31, 2015
Number of Options, Granted		556,952	1,385,000	1,668,995
Exercise price stock option		$ 7.71	$ 12.81	$ 13.41
Subsequent Event [Member] | PRSU's [Member]
Number of Options, Granted	84,000
Executives [Member] | Subsequent Event [Member]
Number of Options, Granted	300,000
Exercise price stock option	$ 3.19
Directors [Member] | Subsequent Event [Member]
Number of Options, Granted	180,000
Exercise price stock option	$ 3.19